PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 1A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 
TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 
3 LOTS OF RESPI[INVESTIGATOR_153603] (RSV) PREFUSION F SUBUNIT 
VACCINE IN HEALTHY ADULTS
Study Intervention Number: PF-06928316 
Study Intervention Name: [CONTACT_130751][INVESTIGATOR_14250] (RSV) Vaccine 
US IND Number:EudraCT Number: N/A
ClinicalTrials.gov ID: TBD
Protocol Number: C3671014
Phase: 3
Brief Title: Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to 
≤49 Years of Age
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be 
promptly notified.
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970217] of country  health authorities and IRBs/ECs and any  protocol administrative change 
letter(s).
Protocol Amendment Summary of Changes Table
Amendment 1 ( 08Feb2022)
Overall Rationale for the Amendment: Increasing the overall sample size of the study.
Section # and 
Nam eDescription of Change Brief Rationale
1.1Synopsis ,
1.2Schema, 
4.1Overall Design ,
and9Statistical 
ConsiderationsSample size was increased and the estimated enrollment 
period was removed.
Statistical methods , including sample size and pow er 
calculations, were updated.In response to CBER 
feedback .
2.2.[ADDRESS_970218] a typographical 
error.
9.3.2 Primary 
Endpoint(s)The d efinition of aTier 2 event wasupdated. To align with other studies 
within the program.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970219] OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................13
1.3. Schedule of Activities .............................................................................................14
2. INTRODUCTION ...............................................................................................................15
2.1. Study  Rationa le.......................................................................................................16
2.2. Background .............................................................................................................16
2.2.1. Clinical Overview .......................................................................................17
2.3. Benefit/Risk Assessment
.........................................................................................18
2.3.1. Risk Assessment
.........................................................................................19
2.3.2. Benefit Assessment .....................................................................................21
2.3.3. Overall Benefit/Risk Conclusion ................................................................21
3. OBJECTI VES, ESTIM
ANDS, AND ENDPOINTS ...........................................................21
4. STUDY DESIGN .................................................................................................................23
4.1. Overall Design .........................................................................................................23
4.2. Scientific Rationale for Study  Design .....................................................................23
4.2.1. Choice of Contraception/Barrier Requirements .........................................23
4.2.2. Diversity  of Study  Population ....................................................................24
4.3. Justification for Dose ..............................................................................................24
4.4. End of Study  Definition ..........................................................................................25
5. STUDY POPUL ATION
......................................................................................................25
5.1. I nclusion Criteria .....................................................................................................25
5.2. Exclu sion Criteria ....................................................................................................26
5.3. L ifesty le Considerations ..........................................................................................27
5.3.1. Contraception ..............................................................................................27
5.4. Screen Failures ........................................................................................................28
5.5. Criteri a for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ...........................28
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY ................................ .28
6.1. Study  Intervention(s) Administered ........................................................................29

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 46.1.1. Administration ............................................................................................30
6.1.2. Medic al Devices .........................................................................................30
6.2. Preparation, Handling, Storage, and Accountability ...............................................30
6.2.1. Preparation and Dispensing ........................................................................31
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................32
6.3.1. Allocation to Study Intervention ................................................................32
6.3.2. Blinding Arrangements ...............................................................................32
[IP_ADDRESS]. Blinding of Study  Site Pers
onnel ..............................................32
[IP_ADDRESS]. Blinding of the Sponsor
.............................................................32
6.3.3. Breaking the Blind ......................................................................................32
6.4. Stu dy Intervention Compliance ...............................................................................33
6.5. Dose Modification ...................................................................................................33
6.6. Continued Access to Study  Intervention After the End of the Study ......................33
6.7. Treatment of Overdose............................................................................................33
6.8. Concomitant Therapy ..............................................................................................33
6.8.1. Prohibited Concomitant Vaccinations and Medications
.............................33
6.8.2. Withholding Periods for Concomitant Vaccinations and Medications
......34
6.8.3. Permitted Nonstudy  Vaccines and Medications During the Study ............34
6.8.4. Recording Nonstudy  Vaccinations and Concomitant Medications ............35
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................35
7.1. Discontinuation of Study  Intervention ....................................................................35
7.1.1. Pregnancy ...................................................................................................35
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_970220] to Follow -Up...................................................................................................37
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 37
8.1. Efficacy  and/or Immunogenicity Assessments .......................................................38
8.1.1. Efficacy  Assessments .................................................................................38
8.1.2. I mmunogenicit y Assessments ................................ ................................ ....38
[IP_ADDRESS]. Blood Collection .......................................................................38
[IP_ADDRESS]. RSV Vaccine Antibody  Testing ................................................38

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 58.1.3. Biological Samples .....................................................................................39
8.2. Safety Assessments .................................................................................................39
8.2.1. Physical Examinations................................................................................398.2.2. Vital Signs ..................................................................................................408.2.3. Clinical Safety La boratory Asse ssments ....................................................40
8.2.4. Electronic Diary..........................................................................................40
[IP_ADDRESS]. Local Reactions – Reactogenicity.............................................[IP_ADDRESS]. Systemic Events ........................................................................[IP_ADDRESS]. Fever Monitoring.......................................................................43
8.2.5. Pregnancy Testing ......................................................................................44
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................44
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......45
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................45
8.3.2. Method of Detecting AEs and SAEs ..........................................................468.3.3. Follow-Up of AEs and SAEs......................................................................468.3.4. Regulatory Reporting Requirements for SAEs...........................................468.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................46
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................49
8.3.6. Cardiovascular and Death Events...............................................................498.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_970221].............................................................498.3.9. Medical Device Deficiencies......................................................................49
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies .........[IP_ADDRESS]. Follow-Up of Medical Device Deficiencies..............................50
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to the Sponsor ........50CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Regulatory Reporting Requirements for Device 
Deficiencies .......................................................................................50
8.3.10. Medication Errors .....................................................................................51
8.4. Pharmacokinetics ....................................................................................................528.5. Genetics.................................................................................................................. .52
8.6. Biomarkers ..............................................................................................................528.7. Immunogenicity Assessments .................................................................................528.8. Health Economics ...................................................................................................528.9. Study P rocedures.....................................................................................................52
8.9.1. Visit 1 – Vaccination (Clinic, Day 1) .........................................................528.9.2. Visit 2 – 1-Month Follow-Up (Clinic, 28 to 35 Days After Visit 1)..........558.9.3. Unscheduled Reactogenicity Visits for a Grade 3 or Suspected Grade 
4 Reaction ........................................................................................................55
9. STATISTICAL C ONSIDERATIONS ................................................................................56
9.1. Statistical Hypotheses .............................................................................................56
9.1.1. Estimands....................................................................................................569.1.2. Statistical Hypotheses.................................................................................579.1.3. Multiplicity Ad justment..............................................................................57
9.2. Analysis Sets ...........................................................................................................579.3. Statistical Analyses .................................................................................................58
9.3.1. General Considerations...............................................................................58
[IP_ADDRESS]. Analyses for Bi nary Data ..........................................................58
[IP_ADDRESS]. Analyses for Continuous Data...................................................58
9.3.2. Primary Endpoint(s)....................................................................................599.3.3. Secondary Endpoint(s)................................................................................60
9.4. Interim Analyses .....................................................................................................61
9.5. Sample Size Determination.....................................................................................61
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................63
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............63
10.1.1. Regulatory and Ethical Considerations ....................................................63
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP ................................ ................................ ......... 63
10.1.2. Financial Disclosure .................................................................................64
10.1.3. I nformed Consent Process ........................................................................64
10.1.4. Data Protection .........................................................................................65
10.1.5. Committees Structure ...............................................................................65
[IP_ADDRESS]. Data Monitoring Committee ...................................................65
10.1.6. Dissemination of Clinical Study  Data ......................................................65
10.1.7. Data Qualit y Assurance ............................................................................67
10.1.8. Source Documents ....................................................................................68
10.1.9. Study  and Site Start and Closure ..............................................................68
10.1.10. Publication Policy ...................................................................................69
10.1.11. Sponsor’s Qualified Medical Personnel .................................................70
10.2. Appendix 2: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................71
10.2.1. Definition of AE .......................................................................................71
10.2.2. Definition of an SAE ................................................................................72
10.2.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................74
10.2.4. Reporting of SAEs
....................................................................................77
10.3. Appendix 3: Contraceptive and Barrier Guidance ................................................78
10.3.1. Male Participant Reproductive Inclusion Criteria
....................................78
10.3.2. Female Participant Reproductive Inclusion Cr iteria .................................78
10.3.3. Woman of Childbearing Potential ............................................................79
10.3.4. Contraception Methods .............................................................................79
10.4. Appendix 4: L iver Safety : Suggested Actions and Follow -Up Assessments .......81
10.5. Appendix 5: AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs, and Devi ce 
Deficiencies: Definitions and Procedures for Recording, Evaluating, 
Follow -
Up, and Reporting in Medical Device Studies .............................................83
10.5.1. Definition of AE and ADE ................................ ................................ .......83
10.5.2. Definition of SAE, SADE, and [LOCATION_003]DE ..................................................83
10.5.3. Definition of Device Deficiency ...............................................................84

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 810.5.4. Recording/Reporting and Follow -Up of Medical Device 
Deficiencies ................................ ................................ ................................ ......84
10.5.5. Reporting of SAEs....................................................................................86
10.5.6. Reporting of SADEs .................................................................................86
10.6. Appendix 6: Alternative Measures During Public Emergencies ..........................87
10.6.1. Telehealth Visits .......................................................................................87
10.7. Appendix 7: Abbreviations
...................................................................................[ADDRESS_970222] OF TABLES
Table 1.
Grading Scale for Local Reactions...........................................................41
Table 2. Grading Scale for S ystemic Events ..........................................................42
Table 3. Ranges for Fever .......................................................................................44
Table 4. Power for the Primary  Immunogenicit y Objective (Lot 
Consistency )
.............................................................................................62

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY
1.1.Synopsis
Brief Title: Clinical L ot Consistency  for RSVpreF in a Population of Healthy  Adults 18 to 
≤49 Years of Age
Indicat ion
[COMPANY_007]’s RSV stabilized prefusion F subunit vaccine (RSVpreF) is a proph ylactic vaccine that
is being developed for 2 indications:
Maternal: Prevention of LRTI-RSV in infants by [CONTACT_712906].
Older Adult: Prevention of RSV- associated msLTRI in adults 60 y ears of age and older 
via active immunization.
Rationale
As of June 2021, RSVpreF has been studied in 3 completed and 3ongoing clinical trials in 
healthy  adults and pregnant women. RSVpreF was shown to be well tolerated, with an
acceptable safet y profile ,and was highl y efficacious in the RSV human challenge model
(Section 2.2.1).
This study  will examine the immune response and the safet y and tolerability profile s across 
3manufactured lots of RSVpreF when administered as a single [ADDRESS_970223] 
RSV disease in infants through maternal immunization and in older adult s through active
vaccination.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 10Objectives , Estimands, and Endpoints
Study Objectives, Estimands ,and Endpoints 
Objective s Estimands Endpoints
Prim ary Immunogenicity 
To demonstrate that the immune 
responses induced by 
3RSVpreF lots ( Group s 1, 2 ,
and 3) 1 month after vaccination 
are equivalent.Theratio of neutralizing
GMTs obtained 1 month after 
vaccination for every pair of 
RSVpreF lots 
(Group 1/Group 2, 
Group 1/Group 3, 
Group 2/Group 3) for RSV A 
and RSV B neutralization 
assays , in participant s 
receiving 1 dose of study 
intervention and in compliance 
with the key protocol criteria 
(evaluable participants) .RSV A and RSV B NTs.
Prim ary Safety 
To evaluate the safety and 
tolerability profiles of 
3RSVpreF lots ( Group s 1, 2 ,
and 3 ).The incidence rate of each 
safety outcome in participants 
receiving 1 dose of the study 
intervention , estimated by [CONTACT_712907] , in the pooled 
RSVpreF lots and placebo.Local reactions (redness, 
swelling, and pain at the 
injection site) self -reported 
on e-diaries for 7 days after 
vaccination.
Systemic events (fever, 
fatigue, headache, vomiting, 
nausea, diarrhea, muscle 
pain, and joint pain) 
self-reported on e -diaries for 
7days af ter vaccination.
AEs from the day of consent 
through study completion .
SAEs from the day of 
consent through study 
completion.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 11CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 12Overall Design
Brief Summary
This Phase 3, multicenter, parallel -group, placebo -controlled, randomized, double -blind 
study willbe conducted in the US .
Health y adults 18 to ≤49 y ears of age will be enrolled and randomized in a 1:1:1:1 ratio to 
receive 1 of 3 lots of RSVpreF ( Group 1: Group 2: Group 3) or placebo.
There are [ADDRESS_970224] blood samples for 
imm
unogenicit y assessments collected both prior to vaccination (Visit 1) and 1 month after 
vaccination (Visit 2).
Local reactions (redness, swelling, and pain at the injection site) occurring at the RSVpreF or 
placebo injection site and sy stemic events (fever, fatigue, headache, vomiting, nausea, 
diarrhea , muscle pain, and joint pain) occurring within 7 day s after vaccination will be 
prompted for and collected daily  by [CONTACT_712908] e -diary  device or smartphone 
application.
AEs and SAEs will be collected from the signing of informed consent through study  
completion ( Visit 2 )
.
Number of Participants
Up to 1000 participants will be enrolled in the study . Allowing for a nonevaluable rate of 
approximately  10%, this will provide the required sample sizeof approximately  900
participants for the evaluable population anal ysis. Participants who withdraw or are 
withdrawn from the study after randomization will not be replaced, regardless of the reason 
for withdrawal.
Intervention Groups and Duration
There will be 4 stud y groups: Group 1, Group 2, Group 3 (representing 3 RSVpreF 
manufacturing lots) ,and placebo. Up to
1000 participants will be randoml y assigned in a 
1:1:1:1 ratio so that each group numbers approximately  250 participants. Each randomize d 
participant will receive his or her vaccine
assignment, administered as a single IM injection 
into the deltoid muscle (nondominant arm preferred) at Visit 1. Participants and study  
personnel will be blinded to intervention groups and assignments.
The las t study  visit for each participant will be approximately  1 month after vaccination. 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 13Statistical Methods
Equivalence of the 3 RSVpreF lots will be assessed by [CONTACT_2329] 2 -sided 95% CI s for ratios of 
lot-specific GMTs. Equivalence will be declared using a 1.5-f old criterion, ie, that the 95% 
CI for the ratio of GMTs for every  pair of RSVpreF lots must be contained in the interval 
(0.667, 1.5), for both antigens simultaneousl y. CIs will be derived b y calculating differences 
in means and CIs for natural log titers (based on the t -distribution) and then exponentiating 
the results.
Safety  will be summarized using counts, percentages ,and incidences of local reactions, 
systemic events, AEs, and SAEs . Incidence rates of local reactions, s ystemic events, AEs , 
and SAEs after vaccination in the combined RSVpreF group relative to the incidence rates in 
the placebo group will be reported.
1.2.Schema
Healthy Adults
18 to ≤ 49 Years of Age
Visit 1
Day 1:
VaccinationVisit 2
1-Month
Follow -UpRandomization 
RatioRandomized
(n)
1 250 RSVpreF Group 1a
1 MonthRSVpreF Group 1
1 250 RSVpreF Group 2aRSVpreF Group 2
1 250 RSVpreF Group 3aRSVpreF Group 3
1 250 PlacebobPlacebo
Blood sampling
Vaccination
Safety assessmentsBlood sampling
Safety assessments
a.RSVpreF Groups 1 through 3 are administered a 120 -µgdose of 1 of 3 RSVpreF manufacturing lots.
b.The placebo group is administered a matching volume containing excipi[INVESTIGATOR_712880], containing no RSVpreF antigens.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 141.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to Study  
Assessments and Procedures in Section 8 for detailed information on each procedure and 
assessment required for compliance with the protocol.
The investigator may  sche dule visits (unplanned visits) in addition to those listed 
in the SoA
table , in order to conduct evaluations or assessments required to protect the well -being of the 
participant .
Visit Identifier Visit 1 Visit 2
Visit Description Vaccination 1-Month 
Follow -Up
Visit Window Day 1 28 to 35 Days 
After Visit 1
Type of Visit Clinic Clinic
Obtain informed consent X
Obtain participant number via IRT X
Obtain demography and medical history data X
Perform clinical assessment (and physical examination and vital signs if 
deemed necessary)X
Obtain prevaccination temperature (body) X
Confirm negative urine (or serum) pregnancy test (for WOCBP) X
Discuss contraceptive use ( asappropriate) X
Record nonstudy vaccinations X X
Revie w concom itant medication use X X
Revie w inclusion and exclusion criteria and confirm eligibility X
Revie w temporary  delay criteria X
Obtain blood sample for antibody assessment ~20 mLa~[ADDRESS_970225] with app download or issue e -diary, issue measuring device anddigital 
thermometer; provide e -diary trainingX
Study intervention administration X
Postvaccination observation (30minutes) and acute immediate reaction 
assessmentX
Provide study participant with emergency contact [CONTACT_1137] X
Revie w e-diary data ( daily review  during the 7 days following vaccination) X
Revie w e-diary for ongoing reactogenicity, obtain stop dates, collect e- diary X
Record adverse events and serious adverse events and obtain any missing stop 
datesX X
Abbreviations: IRT = interactive response technology; WOCBP = w omen of childbearing p otential.
a.Blood sample must be collected before vaccination.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970226], and available proph ylactic measures (ie, RSV 
monoclonal antibody ) are limited to use in only  those infants at highest risk; additionally , in 
LMICs, use of available RSV prophy laxis is cost -prohibitive.11,12While active immunization 
against RSV in infants might be an option, multiple efforts extending over half a century  to 
develop a safe and effective RSV vaccine to protect infants from disease have y ielded little 
success. The earl y peak of disease prese nts a further obstacle to an active vaccination 
strategy  for infants. Given these challenges, maternal immunization to protect infants earl y in 
life offers an attractive strategy  for infant disease prevention.
In addition to infants and y oung children, adults ≥60 y ears of age are at increased risk of 
RSV infection, which can trigger exacerbations of underl ying comorbid conditions such as 
COPD and CHF.13RSV infection has been associated with up to 22% of acute COPD 
exacerbations in prospective cohort studies and 11% of wintertime hospi[INVESTIGATOR_712881].14Current epi[INVESTIGATOR_712882]  177,000 hospi[INVESTIGATOR_4355] 14,000 deaths annuall y in US adults 65 years of 
age and older.13Morbidity is significant among adults hospi[INVESTIGATOR_227913], with 
18% requiring intensive care, 31% needing home health services at discharge, and 26% 
dying within 1 y ear of hospi[INVESTIGATOR_059].15In the US, RSV disease incidence rates in older 
adults are approximately  half those of influenza, with variation y ear to y ear.16Incidence rate 
and risk for severe complications from RSV infection are higher among 
immunocompromised adults and those with chronic conditions (eg,cardiopulmonary  or renal 
disease, hematological malignancies, receipt of chemotherap y,or HIV infection ).17,18
However, the burden of adult RSV disease could be underestimated since testing for RSV is 
less common in old er adults than in children. RSV disease in adults is also difficult to 
diagnose based on clinical signs and s ymptoms alone, and, prior to the broader use of more 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970227] potent 
neutralizing antibodies from postinfection human sera target the prefusion form. RSVpreF is 
composed of engineered, stabilized, trimeric, prefusion F gl ycoproteins matching the 
2subgroups (A and B) to help ensure the broadest coverage against RSV illness
.
RSVpreF is being developed for 2 indications: 
Maternal: Prevention of LRTI-RSV in infants by [CONTACT_712906].
Older Adult: Prevention of RSV -associated msLRTI in adults 60 y ears of age and olde r 
via active immunization.
As of June 2021, RSVpreF has been studied in 3 completed and 3ongoing clinical trials 
in healthy  adults and pregnant women. RSVpreF was shown to be well tolerated, with an 
acceptable safet y profile ,and highl y efficacious in the human challenge model 
(Section 2.2.1).

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 172.2.1. Clinical Overview
Maternal Program Studies
The maternal program includes Phase 2b and 3 studies in pregnant women and a Phase 2b 
study in nonpregnant women.
•C3671003 is a completed Phase 2b multicenter, randomized, placebo-controlled study in 
up to 650 healthy pregnant women 18 through 49 years of age who received RSVpreF at 120 μg and 240 μg, formulated with or without Al(OH)
3, or placebo. 
 
 
•C3671004 is a completed Phase 2b study of 713 healthy nonpregnant women 18 through 
49 years of age. A total of 709 participants received 120 μg RSVpreF or 240 μg 
RSVpreF with Al(OH) 3or placebo, administered with or without concomitant Tdap. The 
study demonstrated a good safety and tolerability profile, high immune responses, and noninferiority of the responses to RSVpreF when coadministered with Tdap, with RSV A and RSV B 50% NT GMRs of 0.97 and 0.96 at 1 month after vaccination.
•C3671008 is an ongoing Phase [ADDRESS_970228] medically attended LRTI in infants. Healthy women ≤49 years of age who are between 24 and 36 weeks of gestation receive 
either RSVpreF 120 μg or placebo.
 
Adult Program Studies
The older adult program includes 2 Phase 1/2 studies, the human challenge study, and the 
planned Phase 3 study.
•In the Phase 1/2 study (C3671001), 1233 healthy adults 18 through 49 and 50 through 
85 years of age received the 3 dose levels of RSVpreF (60 μg, 120 μg, and 240 μg), with 
or without Al(OH)
3, or placebo, administered with or without concomitant influenza 
vaccine. The results have shown that the vaccine was well tolerated and immunogenic in both age groups. RSVpreF elicited robust neutralizing responses against RSV A and RSV B 1 month after vaccination for both age groups across all vaccine dose levels and formulations; these responses remained high through the 12 months after vaccination. In 616 vaccinated participants in the 50- through 85-year age group, RSV 50% NT GMFRs were high across all arms, ranging from [ADDRESS_970229] reported local reactions or systemic events were mild or moderate in severity. The proportions of CCI
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 18participants reporting AEs were generally similar across RSVpreF groups, and no SAEs 
were considered related to the investigational vaccine.
•Phase 1/2 study C3671002, in 250 older adults 65 through 85 years of age, studied the 
3 dose levels of RSVpreF with Al(OH) 3, or CpG/Al(OH) 3(60 μg, 120 μg, and 240 μg), 
given as a single dose or on a schedule of 2 doses administered 2 months apart. All RSVpreF doses and formulations elicited high RSV A and RSV B neutralizing antibody GMTs 1 month after vaccination (GMFRs ranging from 4.8 to 11.6 and 4.5 to 14.1, respectively). CpG-containing formulations did not further increase neutralizing GMTs compared to RSVpreF with or without Al(OH)
3. GMTs in all groups declined, but 
remained higher than baseline (before vaccination) and placebo (SIIV only) at 12 months after vaccination (GMFRs ranging from 2.1 to 3.5 and 2.2 to 4.3, respectively). No increase in GMTs was observed 1 month after Vaccination 2 (GMFR of 0.9). All doses and formulations were safe and well tolerated.
•A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the 
Safety, Immunogenicity and Efficacy of a Respi[INVESTIGATOR_322011] (RSVpreF) 
in a Virus Challenge Model in Healthy Adults ([STUDY_ID_REMOVED]) was conducted by [CONTACT_712909] 70 healthy participants 18 to 50 years of age. Participants received a single dose of 
either 120 μg RSVpreF or placebo, and 4 weeks later underwent intranasal challenge with 
RSV-A Memphis 37b virus. The immunogenicity and efficacy of RSVpreF vaccination on virus replication, clinical symptoms, and incidence of symptomatic RSV infection were evaluated. The primary analysis of the human challenge study showed that a 120-μg dose of RSVpreF is well tolerated and has an acceptable safety profile. The study 
has demonstrated 100% efficacy of RSVpreF against RT-PCR–confirmed symptomatic respi[INVESTIGATOR_712883] a mild-to-moderate disease model.
•C3671013 is an ongoing Phase 3, multicenter, randomized, double-blind, 
placebo-controlled study to assess the safety, immunogenicity, and efficacy of [COMPANY_007]’s RSVpreF in prevention of RSV-associated ms LRTI in adults [ADDRESS_970230] RSV season and the long-term immunogenicity and efficacy of RSVpreF across multiple RSV seasons. Both healthy adults and adults with stable chronic diseases are included. Approximately 10% of participants with stable chronic cardiopulmonary conditions such as COPD, asthma, or CHF are being enrolled.
 
2.3. Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of RSVpreF may be found in the IB, which is the SRSD for this study.CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 192.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) :RSV preF
Local and systemic reactions to 
the vaccine may occur 
(injection site redness, injection 
site swelling, and injection site 
pain; fever, fatigue, headache, 
chills, muscle pain, and joint 
pain) following vaccination.These are common adverse reactions seen with other vaccines20as 
well as RSVp reF.The most common events reported in the FIH
C3671001 st udy were mild to moderate pain at the injection site, 
fatigue, headache, and muscle pain.The study employs the use of a reactogenicity 
e-diary ,which allows the investigator to monitor 
local reactions and systemic events in real time 
through an electronic portal. Severe reactions will 
require an unscheduled telephone call, and visit if 
required, to be conducted per protocol.
All study participant s will be observed for at least 
30 minutes after vaccination.
Safety profile of a novel 
vaccine close to being, but not 
yet fully ,characterized.Data available from completed and ongoing studies showed a low 
incidence of severe or serious events, and no clinically concerning 
safety observations. The vaccine appears to be safe and w ell
tolerated across the safety population and within demographic 
subgroups based on age, sex, andrace/ethnicity.Collection and review of AEs and SAEs 
throughout the study.
All participants will be observed for at least 
30minutes after vaccination.
Theoretical risk for RSV 
enhancement.RSVpreF is being evaluated in ongoing clinical studies. [COMPANY_007]’s 
immunization approach circumvents the risk of vaccine -mediated 
disease enhanc ement that was observed in the 1960s following direct 
immunization of RSV -naive infants with a nFI-RSV. FI -RSV 
elicited a predominantly nonneutralizing antibody response and a 
Th2-biased cell -mediated response, both of which are considered 
potential contri buting factors to disease enhancement. During 
preclinical studies, in a standard cotton rat infectious RSV challenge 
model, FI -RSV showed pathological signs of causing disease 
enhancement, and the current [COMPANY_007] vaccine candidate, RSVpreF, 
did not. Most im portant, RSV vaccine -mediated disease 
enhancement has not been reported to occur in RSV -experienced 
individuals after vaccination with any RSV vaccine candidate. 
Because older adults are universally RSV -experienced, they are not 
considered at risk for a di sease- enhancing immune response to the 
vaccine that could exacerbate infection in themselves.Collection and review of AEs and SAEs 
throughout the study.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 20Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Procedures 
Venipuncture will be performed 
during the study .There is the risk of bleeding, bruising, hematoma formation, and 
infection at the venipuncture site.Only appropriately qualified personnel will obtain the 
blood draw .
Participants will be required to 
attend healthcare facilities 
during the global SARS -CoV -2 
pandemic.Without appropriate social distancing and PPE, there is a potential 
for increased exposure to SARS -CoV- 2.[COMPANY_007] w ill work with sites to ensure appropriate 
COVID -19 prevention strategies.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 212.3.2. Benefit Assessment
Benefit considerations may  include:
Potential benefit of receiving stud y intervention that may have clinical utility  in the 
future .
Contributing to the process of developi[INVESTIGATOR_336243].
Medical evaluations/assessments associated with study procedures.
2.3.3. Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk tostudy participants, the potential risks 
identified in association with RSV preF are justified by  [CONTACT_712910] y participants and older participants who may  be at risk of RSV .
3.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Study Objectives, Estimands ,and Endpoints
Objective s Estimands Endpoints
Prim ary Immunogenicity
To demonstrate that the immune 
responses induced by 
3RSVpreF lots ( Group s 1, 2,
and 3) 1 month after vaccination 
are equivalent.Theratio of neutralizing
GMTs obtained 1 month after 
vaccination for every pair of 
RSVpreF lots 
(Group 1/Group 2, 
Group 1/Group 3, 
Group 2/Group 3) for RSV A 
and RSV B neutralization 
assays , in participa nts 
receiving 1 dose of study 
intervention and in compliance 
with the key protocol criteria 
(evaluable participants) .RSV A and RSV B NTs.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 22Study Objectives, Estimands, and Endpoints
Objectives Estimands Endpoints
Primary Safety 
To evaluate the safety and 
tolerability profiles of 3 RSVpreF lots (Groups 1, 2,and 3).•The incidence rate of each 
safety outcome in participants receiving 1 dose of the study intervention, estimated by [CONTACT_712911], in the pooled RSVpreF lots and placebo.•Local reactions (redness, 
swelling, and pain at the injection site) self-reported on e-diaries for 7 days after vaccination.
•Systemic events (fever, 
fatigue, headache, vomiting,nausea, diarrhea, muscle pain, and joint pain) 
self-reported on e-diaries for 
7 days after vaccination.
•AEs from the day of consent 
through study completion.
•SAEs from the day of 
consent through study completion.
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 234.STUDY DESIGN
4.1.Overall Design
This Phase 3, multicenter, parallel -group, placebo -controlled, randomized, double -blind 
study will be conducted in the US . Up to 1000 healthy  women and men 18 to ≤49years of 
age will be enrolled .
There are [ADDRESS_970231] blood samples for immunogenicit y 
assessments collected both p rior to vaccination (Visit 1) and 1 month after vaccination
(Visit 2).
Local reactions (redness, swelling, and pain at the injection site) occurring at the RSVpreF or 
placebo injection site and sy stemic events (fever, fatigue, headache, vomiting, nausea, 
diarrhea, muscle pain, and joint pain) occurring within 7 day s after vaccination will be 
prompted for and collected daily  by [CONTACT_712908] e -diary  device or smartphone 
application.
AEs and SAEs will be collected from the signing of informed consent through Visit 2.
Number of Participants
Up to 1000 participants will be enrolled in th e study . Allowing for a nonevaluable rate of 
approximately  10% , this will provide the required sample size of approximately
 
900participants for the evaluable population analy sis. Participants who withdraw or are 
withdrawn from the study after randomization will not be replaced, regardless of the reason 
for withdrawal.
Intervention Groups and Duration
There will be 4 stud y groups: Group 1, Group 2, Group 3 (representing 3 RSVpreF 
manufacturing lots) ,and placebo. Up to 1000 participants will be randoml y assigned in a 
1:1:1:1 ratio so that each group numbers approximately  250 participants. Each randomized 
participant will receive 
his or her vaccine assignment, administered as a single IM injection 
into the deltoid muscle (nondominant arm preferred ) at Visit 1. Participants and study  
personnel will be blinded to intervention groups and assignments.
The last study  visit for each participant will be approximately  1 month after vaccination.
4.2.Scientific Rationale for Study Design
See Section 2.1.
4.2.1.
Choice of Contraception/Barrier Requirements
There is no suspi[INVESTIGATOR_603698] y based on the intended pharmacology  of the 
compound ;however ,human reproductive safety  data are l imited for RSVpreF .Therefore, the 
use of a highl y effective method of contraception is required (see Section 10.3 ) .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 244.2.2. Diversity of Stud y Population
To the extent possible, recruitment attempts will be made to enroll participants so that the 
study  demographic profile approximates the general population. Reasonable attempts will be 
made to enroll participants with the distribution of characteristics shown below:
Race US Census Data21
Target for C367101 4
Black or African American 13.4%
Asian 5.9%
American Indian or Alaska Native 1.3%
Native Hawaiian or other Pacific Islander 0.2%
White 76.3%
Ethnicity US Census Data
Target for C367101 4
Hispanic or Latino(a) or of Spanish origin 18.5%
4.3.Justification for Dose
The final dose and formulation of RSVpreF selected for use in this study  is based on the 
safet y and immunogenicity data from 3 Phase 1/2 studies and the efficacy  evaluation in the 
human challenge stud y.
The FIH study  in adults 18 through 85 years of age evaluated the safety , tolerability , and 
immunogenicit y of 3 escalating dose levels of 60 μg, 120 μg, and 240 μg, with or without 
Al(OH )3, when administered alone or concomitantly  with SIIV (C3671001).
A study  in older adults 65 
through 85 years of age evaluated the safet y, tolerability ,and 
immunogenicit y of 60 -μg, 120- μg, and 240 -μg RSVpreF doses formulated with 
Al(OH) 3or CpG/Al(OH) 3adjuvant, or 240 µg RSVpreF with RSV antigens alone, when 
administered concomitantly  with SIIV (C3671002).
A study  in pregnant women 18 
through 49 years of age evaluated the safety, tolerability ,
and immunogenicit y of 120 -µg and 240 -μg RSVpreF dose levels w ith and without 
Al(OH) 3(C3671003).
A study  in healthy  adults 18 through 50 years of age evaluated the safety , tolerability , 
immunogenicit y,and efficacy  of 120 µg RSVpreF in a virus challenge model 
([STUDY_ID_REMOVED]) .
Based on the Phase 1/2 studies (C3671001 and C3671002), no substantial differences were 
observed between the immunogenicit y or reactogenicity  of 120- µg and 240 -µg dose levels or 
of formulations with and without Al(OH) 3or CpG/Al(OH) 3. Therefore, the 120 -µg
without -Al(OH) 3formulation was chosen for the human challenge stud y.The acceptable 
reactogenicity  and safet y profile along with the high efficacy  demonstrated in the 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970232] completed the study  when she/hehas comple ted all study  
visits and procedures .
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate 
participant s are enrolled , including 
participants across diverse and representative racial and ethnic backgrounds. Use of a 
prescreener for study  recruitment purposes will include collection of information that reflects 
the enrollment of a diverse participant population including, where permitted under local 
regulations, age, sex, race, and ethnicit y. The following eligibility  criteria are desig ned to 
select participant s for whom participation in the study  is considered appropriate. All relevant 
medical and nonmedical conditions should be taken into consideration when deciding 
whether a particular participant is suitable for this protocol
.
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if allthe following criteria appl y:
Age and Sex:
1.Health y males or nonpregnant, nonbreastfeeding females between the ages of 18 and 
≤49years, inclusive, at Visit 1 (Day  1).
Refer to Appendix 3 for reproductive criteria for male ( Section 10.3.1) andfemale 
(Section 10.3.2) participants.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with scheduled visits, laboratory tests, 
lifesty le considerations, and other study  procedures, including dail y completion of the 
e
-diary  for 7days after study  vaccination.
3.Health y participants as determined b y medical history, ph ysical examination (if required) , 
and the clinical judgment of the investigator to be eligible for inclusion in the study . 
Participants with preexisting chronic medica l conditions determined to be stable in the 
clinical judgment of the investigator may be included.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 26Informed Consent:
4.Capable of giving signed informed consent as described in Appendix 1 , which includes 
compliance with the requirements and restrictions listed in the I CD and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1. Bleeding diathesis or condition associated with prolonged bleeding time that may  
contraindicate IMinjection .
2.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  intervention or any  related 
vaccine .
3.Unstable chronic medical condition or disease requiring significant change in therap yaor 
hospi[INVESTIGATOR_232992] 3 months before receipt of study  
intervention .
4. Immunocompromised individuals with known or suspected immunodeficiency , as 
determined b y history  and/or laboratory /physical examination.
5.Known infection with HIV, HCV, or HBV.
6.Other medical or psy chiatric condition including recent (within the past year) or active 
suicidal ideation /behavior or laboratory  abnormality  that may  increase the risk ofstudy  
partic ipation or, in the investigator’s judgment, make the participant inappropriate for the
study .
Prior/Concomitant Therapy:
7.Previous vaccination with any  licensed or investigational RSV vaccine at any  time prior 
to enrollment or planned receipt throughout the study .
8.Receipt of any blood/plasma products or immunoglobulin, from 60 day s before study  
intervention administration or planned receipt throughout the stud y.
                                                
aA change to a new therapy category is considered significant if caused by w orsening disease. A change 
in dose or therapy within a therapy category (eg, change from 1 nonsteroidal anti -inflammatory drug [NSAID] 
to another) is not considered significant.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 279. Receipt of monoclonal antibodies from 60 day s before stud y intervention administration 
or planned receipt throughout the study .
10.Receipt of systemic treatment with known immunosuppressant medications within 
60daysbefore study  intervention administration or the use of s ystemic corticosteroids 
(
≥20 mg/day  of prednisone or equivalent) for ≥14 day s within 28 day s prior to study  
enrollment. Prednisone use of <20 mg/day  for <14 day s is permitted. Inhaled/nebulized, 
intra-articular, intrabursal, or topi[INVESTIGATOR_2855] (skin ,eyes, ears) corticosteroids are permitted.
11. Current alcohol abuse or illicit drug us e.Note: Marijuana use is not considered an 
exclusion criterion for the study  when elicited in participant screening, though it may  be 
considered illicit in some locales.
12.Current use of any prohibited concomitant medication(s) or those unwilling/unable to use 
a permitted concomitant medication(s). Refer to Section 6.8.
Prior/Concurrent Clinical Study Experience:
13.Participation in other s tudies involving investigational drug(s) or investigational vaccines
within 28 day s prior to consent and/or during study  participation.
Other Exclusions:
14.Pregnant females; breastfeeding females; and WOCBP who are unwilling or unable to 
use a highly  
effective method of contraception as outlined in the protocol for the duration 
of the study .
15. Men who are unwilling to co mply  with contraception methods as outlined in the protocol 
for the duration of the study .
16.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the study , 
site staff otherwise supervised by  [CONTACT_093], and their respective family  members.
5.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, w ill confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and partner(s) from the permitted list of contraception methods (see Appendix 3 ,
Section 10.3.4) and will confirm that the participant has been instructed in its consistent and 
correct use. At time points indicated in the SoA,the investigator or designee will inform the 
participant of the need to use highl y effective contraception consistentl y and correctly and 
document the conversation and the participant’s affirmation in the participant’s chart 
(participants need to affirm their consistent and c orrect use of at least 1 of the selected 
methods of contraception) considering that their risk for pregnancy  may  have changed since 
the last visit . In addition, the investigator or designee will instruct the participant to call 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 28immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently randomly  assigne d to study  intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet 
the CONSORT publishing requirements and to respond to queries from regulatory  
authorities. Minimal infor mation includes demography , screen failure details, eligibility  
criteria, and an y SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened under a new participant number .
5.5.Criteria for Temporarily Delaying Enrollment/Randomization/
Administrat ionof 
Study Intervention
The following conditions may  allow a participant to be vaccinated once the conditions have 
resolved and the participant is otherwise eligible:
Current febrile illness ( body  temperature ≥100.4°F [≥38.0°C] ) or other acute illness 
within 48 hours before study  intervention administration.
Receipt of an y inactivated vaccine or any  seasonal or pandemic influenza vaccine
(whether inactivated or LAIV) , licensed COVID- 19 vaccines ,or COVID -19 vac cines 
authorized for temporary or emergency  use within 14 days or any  live vaccine within 
28days before study  intervention administration.
Receipt of short -term (<14 day s) systemic corticosteroids. Study  intervention 
administration should be delay ed until systemic corticosteroid use has been discontinued 
for at least 28 day s. Inhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (skin or ey es) 
corticosteroids are permitted.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  intervention is defined a s any investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study intervention refers tothe RSVpreF and placebo 
(lyophilized cake containing excipi[INVESTIGATOR_712884], containing 
no RSVpreF antigens ).

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 296.1.Study Intervention(s) Administered
Intervention Name [CONTACT_712930].
Dose Form ulation The active ingredients in RSVpreF are [ADDRESS_970233] vial and diluent PFS are designed such that the 
intended vaccine dose is delivered by [CONTACT_712912].
Dosage Level(s) 120 µg RSVpreF by [CONTACT_712913].
Route of 
AdministrationIMinjection into the deltoid muscle of the nondominant arm (preferred).
Use Experimental .
Sourcing RSVpreF will be provided by [CONTACT_17207].
Packaging and 
LabelingThe vaccine will be packaged within cartons labeled by [CONTACT_712914] w ith current guidelines and applicable local and legal regulatory 
requirements.
Intervention Name [CONTACT_712931] .
Dose Form ulation The placebo is supplied as a lyophilized white cake in a 2 -mL glass vial, with a 13 -mm 
lyophilization stopper, aluminum overseal, and flip -off cap. It contains no antigens.
The placebo w ill be reconstituted by a diluent consisting of sterile w ater in a PF S. The 
lyophilized cake contains excipi[INVESTIGATOR_11792], after reconstitution, w ill yield a volume 
matching the RSVpreF.
The fill volume of the placebo vial and diluent PFS is delivered by [CONTACT_712915].
Dosage Level(s) N/A
Route of 
AdministrationIMinjection into the deltoid muscle of the nondom inant arm (preferred) .
Use Placebo control .
Sourcing Placebo w ill be provided by [CONTACT_17207].
Packaging and 
LabelingThe vaccine will be packaged within cartons labeled by [CONTACT_712914] w ith current guidelines and applicable local and legal regulatory 
requirements.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 306.1.1. Administration
Participants will receive 1 dose of study  intervention as randomized at the vaccination visit 
(Day  1) in accordance with the study ’s SoA. The study  intervention will be administered 
intramuscularl y by [CONTACT_712916], 
preferabl y of the nondominant arm, unless medically co ntraindicated, in which case the 
injection may  be administered in the dominant arm. Study intervention administration will be 
performed b y appropriately  designated blinded study  staff at the investigator site.
Standard vaccination practices must be observe d, and vaccine must not be injected into blood 
vessels. Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of study  interventions should be performed b y an appropriately  qualified, 
GCP -trained, and vaccine- experienced member of the study  staff (eg, ph ysician, nurse, 
physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as al lowed b y 
local, state, and institutional guidance.
Study  intervention administration details will be recorded on the CRF and pharmacy /study  
records.
6.1.2. Medical Devices 
In this stud y,medical devices being deplo yed are for the reconstitution diluent for the s tudy 
intervention (RSVpreF or placebo ). The study  intervention supplies are provided in a kit that 
contains the study  intervention (RSV preF or placebo), a PFS containing sterile water, and a 
vial adapter .
Instructions for medical device use are provided in the IPmanual.
Medical device deficiencies
, including those resulting from malfunctions of the device, must 
be detected, documented, and reported b y the study personnel throughout the study.
Please refer to Section 8.3.[ADDRESS_970234] be stored in a secure, environmentally
 controlled, and monitored 
(manual or automated recording ) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970235] be quarantined and not used until [COMPANY_007] provides permission
to use the study  intervention. Speci fic details regarding the definition of an excursion
and information the site should report for each excursion will be provided to the site
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_712917] t he label.
5.Study  interventions should be stored in their original containers.
6.See the IP manual for storage conditions of the study  intervention once reconstituted.
7.The investigator, institution, or the head of the medical institution (where applicable)
is responsible for study intervention accountability, reconciliation, and record
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the
IPAL or sponsor -approved equivalent . All study  intervention s will be accounted for
using a study intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study
interventions are provided in the I P manual. All destruction must be adequately
documented. If destruction is authorized to take place at the investigator site, the
investigator must ensure that the materials are destroy ed in compliance with
applicable environmental regulations, institutional policy , and any  special instructions
provided b y [COMPANY_007].
Upon identification of a product complai nt, notify the sponsor w ithin 1 business day  of 
discovery as described in the I P manual.
6.2.1. Preparation and Dispensing
See the IP manual for instructions on how to prepare the stud y intervention for 
administration. Study  intervention should be prepared and dispensed by  [CONTACT_36534] y 
medically  qualified and experienced member of the study  staff (eg, phy sician, nurse, 
physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as 
allowed b y local, state, and institutional guidan ce. A second staff member will verify  the 
preparation and dispensing.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 326.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation (randomization) of participants to vaccine groups will proceed through the use of 
an IRTsystem (I WR). The site personnel (study  coordinator or specified designee) will be 
required to enter or select information including but not limited to the user’s I D and 
password, the protocol number, and the participant number. The site personnel will th en be 
provided with a vaccine assignment, randomization number, and DU or container number 
when study  intervention is being supplied via the IRT sy stem. The IRT s ystem will provide a 
confirmation report containing the participant number, randomization numb er, and DU or 
container number assigned. The confirmation report must be stored in the site’s files.
Study  intervention will be dispensed and administered at study  Visit [ADDRESS_970236] information 
and further details on the use of the IRT s ystem.
6.3.2. Blinding Arrangements
The study  is double -blind.
[IP_ADDRESS]. Blinding of Study Site Personnel
The participant, study coordinator, and all site staff will be blinded.
Please refer to the IP manual for further details.
[IP_ADDRESS]. Blinding of the Sponsor
The majority of sponsor staff will be blinded to study intervention allocation . All laboratory  
testing 
personnel performing serology  assay s or diagnostic assay s will remain blinded to 
study  intervention assigned/received throughout the study .
6.3.3. Breaking the Blind
The I RT will be programmed with blind -breaking instructions. I n case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
vaccine assignment is warranted. Participant safety  must alway s be the first consideration in 
making such a determination. I f the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact [CONTACT_1152] a 
participant’s vaccine assignment unless this could delay  further management of the 
participant. If a participant’s vaccine assignment is unblinded, the sponsor must be notified 
within [ADDRESS_970237] information 
and further details on the use of the IRT s ystem.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970238] is preferred, but it does not preclude the use of an existing 
appropriate clinical site documentation sy stem. The existing clinical site's documentation 
system should capture all pertinent/required information on the preparation and 
administration of the dose. This may  be used in place of the Preparation Record after 
approval from the sponsor and/or designee.
6.5. Dose Modification
This section is not applicable.
6.6.Continued Access to Study Intervention After the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of study  intervention greater than [ADDRESS_970239] udy intervention within 
a 24-hour time period will be considered an overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs.
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
6.8.Concomitant Therapy
6.8.1. Prohibited Concomitant Vaccinations and Medications
Licensed or 
nonstudy  investigational RSV vaccines are prohibited at any  time prior to 
enrollment and thereafter 
during the course of the study .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 34Investigational vaccines and investigational drugs are prohibited within 28 day s prior to 
enrollment and at any time during the stud y.
6.8.2. Withholding Periods for Concomitant Vaccinations and Medications
Unless considered medically  necessary ,the following restrictions apply  to nonstudy  licensed
vaccines and medications as well as COVID -
19 vaccines authorize d for temporary  or 
emergency  use:
COVID -19 vaccines may not be given within 14 day s before or within 7 day s after study  
intervention administration.
Nonstudy  inactivated vaccines orseasonal or pandemic influenza vaccine (whether 
inactivated or LAIV) may not be given within 14 days before or within 7 day s after study  
intervention administration.
Nonstudy  livevaccines should not be given within 28 day s before or within 28days after 
study  intervention administration .
Systemic corticosteroids ( ≥20 mg/da y of prednisone or equivalent) fo r ≥14 day s should 
not be given within 28 days before study  intervention administration through the
conclusion of study participation.
Chronic sy stemic treatment with known immunosuppressant medications should not be 
given within 6 0 day sbefore study  intervention administration through theconclusion of 
study participation.
Monoclonal antibodies should not be given within 60 day s before study  intervention 
administration through the conclusion of stud y participation.
Blood/pl asma products or immunoglobulin should not be given within 60 day s before
study  intervention administration through theconclusion of study participation.
Prophy lactic antipy retics and other pain medication to prevent symptoms associated with 
study  interve ntion administration are not permitted.
6.8.3. Permitted Nonstudy Vaccines and Medications During the Study
The following restrictions apply  to permitted vaccines and medications (except when they  are 
considered medicall y necessary) :
Licensed or authorized COVID -19 vaccines may be given during the study starting 
7days after study  intervention administration (Day 8) .
Nonstudy  inactivated vaccines and seasonal or pandemic influenza vaccine (whether 
inactivated or LAIV) may be given on Day  8, where Day  1 is the day  of study  
intervention administration.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 35Nonstudy  live vaccines may be given starting 28days after study  intervention
administration (Day  29).
Inhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (eg, skin, ey es) corti costeroids 
are permitted. Short -term use of systemic corticosteroids (equivalent of <20 mg/day  of 
prednisone) for <14 day s prior to the administration of study  intervention ispermitted.
The use of antip yretics and other pain medication to treat symptoms a ssociated with 
study  intervention administration is permitted .
Medication other than that listed in Section 6.8.1 and Section 6.8.2 required for treatment 
of preexisting stable cond itions is permitted.
6.8.4. Recording Nonstudy Vaccinations and Concomitant Medications
Receipt of the following concomitant medications and vaccinations will be recorded in the 
CRF:
All nonstudy  vaccinations received from 28 day s prior to study  enrollment throug hthe
conclusion of study participation.
The following 
medications, although prohibited ( Section 6.8.1), will be collected from 
Visit1 to the end of the study
if required for medical care :
oImmunosuppressant medications .
oMonoclonal antibodies.
oSystemic corticosteroids, ie, oral, IM, or IV. D o not record topi[INVESTIGATOR_2855], optic, otic, 
inhaled, intra -articular ,or intrabursal corticosteroids.
oBlood/plas ma products or immunoglobulin.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Since this is a single -dose study , this section is not applicable.
7.1.1. Pregnancy
As this is a single -dose study , in the case of a positive confirmed pregnancy after 
vaccination, the participant may  remain in the study and complete study  procedures . Any  
pregnancy  confirmed prior to 
randomi zation will deem the participant as a screen failure.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 367.2.Participant Discontinuation/Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
withdrawal from the study  may  include the following:
Refused further stud y procedures
Lost to follow -up
Death
Study  terminated by  [CONTACT_3211]
Adverse events
Physician decision
Protocol deviation
Participant request
The investigator or his or her designee should capture the re ason for withdrawal in the CRF 
for all participants.
If the participant withdraws from the study  and also withdraws consent (Section 7.2.1) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
If a participant withdraws from the study , he/she may  reque st destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
When a participant withdraws from the stud y because of an SAE, the SAE must be recorded 
on the CRF and reported on the Vaccine SAE Report ingForm.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
Participants who withdraw after randomization will not be replaced .
7.2.1. Withdrawal of Consent
Participants who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The on ly 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_712918]-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 37information. Participants should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or a lso from study  procedures and/or 
postvaccination study  follow -up, and entered on the appropriate CRF page. I n the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Follow -Up
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_46342]. Counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether the participant wishes to and/or should continue in the 
study .
Before a participant is deemed lost to follow- up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_13140]’s 
medical record.
Should the participant continu e to be unreachable, he/she will be considered to have 
withdrawn from the study.
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
The date of birth will be collected to critically  evaluate the immune response and safety  
profile b y age.
Study  procedures and their timing are summarized in theSoA.Protocol waivers or 
exemptions are not allowed.
Safet y issues should be discussed with the sponsor immediately upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, [ADDRESS_970240] information will be provided to the investigator site prior to study initiation.
8.1. Efficacy and/or Immunogenicity Assessments
8.1.1. Efficacy AssessmentsEfficacy assessments are not applicable to this study.
8.1.2. Immunogenicity Assessments
[IP_ADDRESS]. Blood CollectionBlood samples for immunogenicity assessments will be collected from all enrolled 
participants prior to study vaccination at Visit 1 (approximately 20 mL per sample) and at Visit 2 (1 month after Visit 1) (approximately 80 mL per sample).
Instructions for the collection and handling of biological samples will be provided in the 
laboratory manual. The actual date and time of each sample will be recorded.
The immunogenicity samples must be processed and shipped as indicated in the instructions 
provided to the investigator site to maintain sample integrity. Any deviations from the immunogenicity sample-handling procedure (eg, sample collection and processing steps, interim storage, or shippi[INVESTIGATOR_19944]), including any actions taken, must be documented, and reported to the sponsor. On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
[IP_ADDRESS]. RSV Vaccine Antibody Testing
Serum samples will be assayed for RSV A and RSV B serum NTs  
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 39RSV A and RSV B serum NTs will be determined and reported as the NT.  
 
Sample collection, processing, storage, and shippi[INVESTIGATOR_712885]. All assays will be performed by [CONTACT_712919]/or at a facility designated by [CONTACT_4618].
8.1.3. Biological Samples
Blood/serum samples will be used only for scientific research. Each sample will be labeled 
with a code so that the laboratory personnel testing the samples will not know the participant’s identity. Samples that remain after performing assays outlined in the protocol may be stored by [CONTACT_4618]. Unless a time limitation is required by [CONTACT_240846], the samples will be stored for up to 15 years after the end of the study and then destroyed. If allowed by [CONTACT_48355], stored samples may be used for additional testing to better understand the immune responses to the vaccine(s) under study in this protocol, to inform the development of other products, and/or for vaccine-related assay work supporting vaccine programs. No sequencing of the participant’s DNA will be performed.
The participant may request that his/her samples, if still identifiable, be destroyed at any 
time; however, any data already collected from those samples will still be used for this research. The biological samples may be shared with other researchers as long as confidentiality is maintained, and no sequencing of the participant’s DNA is performed.
8.2. Safety Assessments
Participants will be observed for 30 minutes after vaccination and any reactions occurring 
during that time will be recorded as AEs.
Planned time points for all safety assessments are provided in the SoA. Unscheduled clinical 
laboratory measurements may be obtained at  any time during the study to assess any 
perceived safety issues.
8.2.1. Physical Examinations
If the clinical assessment indicates that a physical examination is necessary to 
comprehensively evaluate the participant, a physical examination will be performed.CCI
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970241] p hysical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Section 10.2) must be reported according to the processes in 
Section 8.3.1 toSection 8.3.3 .
8.2.2. Vital Signs
The participant’s bod y temperature will be assessed prior to vaccination.
If the clinical assessment indicates that a ph ysical examination is necessary to
comprehensivel y evaluate the participant, vital signs should also be evaluated. Record an y 
findings in the source documents and, if clinicall y significant, record on the medical history 
CRF.
8.2.3. Clinical Safety Laboratory Assessments
Clinical safety  laboratory assessments will not be collected in this study .
8.2.4. Electronic Diary
Participants will be required to use an e- diary , installed on a provisioned device or as an 
application on a personal device, and will be asked to monitor and record local reactions, 
systemic events, and oral temperature each evening for 7 days following v accination (Day  1 
through Day  7, where Day  1 is the day  of vaccination).
The e -diary  allows recording of these assessments only  within a fixed time window each day , 
thus providing the accurate representation of the participant’s experience at that time.
Data on local reactions, sy stemic events, and oral temperature recorded in the e- diary  will be 
transferred electronically to the e- diary  vendor, where they  will be available for review by  
[CONTACT_431], their qualified designees, and sponsor staff at all tim es via a secure, restricted
internet -based portal. At intervals agreed to by  [CONTACT_407401], these data will be 
transferred electronically to [COMPANY_007] for anal ysis and reporting. These data do not need to be 
recorded b y the investigator in the CRF, ex cept forthe following conditions:
If a participant withdraws because of prompted events recorded in the e -diary , the 
event(s) should be recorded on the AE page of the CRF, regardless of whether the 
investigator considers the event(s) to be clinically  significant.
The investigator or designee must obtain stop dates for an y reactions ongoing on the last 
day that the e -diary  was completed. The stop dates should be documented in the source 
documents and the information entered in the CRF. In the event the reac tion is ongoing at 
the end of the stud y, the reaction will be marked as ongoing.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 41Investigators (or appropriately qualified designees) are required to review the e -diary  data 
online at frequent intervals to evaluate participant compliance and safet y. These 
prospectivel y collected occurrences of local reactions and systemic events are graded as 
described in Table 1, Table 2,and Table 3.
[IP_ADDRESS]. Local Reactions –Reactogenicity
Following vaccination (Day  1 through Day  7, where Day  1 is the day  of vaccination), the 
participants will be asked to assess redness, swelling, and pain at the injection site and to 
record the sy mptoms in the e -diary  or appropriate device, in the evening .
Redness and swelling will be measured b y the participant and recorded in measuring d evice 
units (range: 1 to 21and > 21 ; an entry  in the e- diary  of 21will denote ≥21) and then 
categorized during anal ysis as mild, moderate, or severe based on the grading scale in
Table 1. Measuring device units can be converted to centimeters according to the following 
scale: 1 measuring device unit = 0.[ADDRESS_970242] should 
occur to ascertain further details and determine whether a site visit is clinically indicated.
Only  an investigator or a qualified designee is able to classify  a participant’s local reaction as 
Grade 4, after clinical evaluation of the participant or documentation from another medically  
qualifi ed source (eg, emergency  room or hospi[INVESTIGATOR_8735]) or, in the case of pain at the 
injection site only , contact [CONTACT_6635]. If a participant experiences a Grade [ADDRESS_970243] ion will be 
collected as an AE /SAE on the CRF. The event will be graded using the AE intensity  grading 
scale (Section 10.2.3).
If a lo cal reaction persists bey ond the end of the e -diary  period, the participant will be 
requested to report that information and/or an y new AEs that develop to the investigator
.The 
investigator will enter this additional information in the participant’s sourc e notes and CRF.
Table 1. Grading Scale for Local Reactions
Mild
Grade 1Moderate
Grade 2Severe
Grade 3 Grade 4a
Redness >2.0 cm to 5.0 cm 
(5to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(>20 measuring 
device units)Necrosis or 
exfoliative 
dermatitis
Swelling >2.0 cm to 5.0 cm
(5to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(>20 measuring 
device units)Necrosis

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 42Table 1. Grading Scale for Local Reactions
Mild
Grade 1Moderate
Grade 2Severe
Grade 3 Grade 4a
Pain (at the injection 
site)Does not interfere 
with activityInterferes with 
activit yPrevents daily 
activityEmergency room 
visit or 
hospi[INVESTIGATOR_712886]
a.Only an investigator or qualified designee is able to classify a participant’s local reaction as Grade 4, after 
clinical evaluation of the participant or documentation from another medically qualified source 
(eg,emergency room or hospi[INVESTIGATOR_8735]) or, in the case of pain at the injection site only, contact [CONTACT_151525]. Grade 4 loc al reactions will be collected on the AE case report form and assessed by [CONTACT_712920] 10.2.3 .
[IP_ADDRESS]. Systemic Events
Following vaccination (Day  1 through Day  7, where Day  1 is the day  of vaccination), 
participants will be asked to assess fatigue, headache, vomiting, nausea, diarrhea, muscle 
pain, and joint pain and to record the s ymptoms in the e -diary  that evening. The sy mptoms 
will be asse ssed b y the participant according to the grading scale in Table 2.
If a severe s ystemic event is reported in the reactogenicity  e-diary , a telephone contact [CONTACT_712921] a site visit is clinically
indicated.
Only  an investigator or qualified designee is able to classify  a participant’s sy stemic event as 
Grade 4, after clinical evaluation of the participant or documen tation from another medically  
qualified source (eg, emergency  room or hospi[INVESTIGATOR_8735]) or contact [CONTACT_6635]. If a 
participant experiences a Gr ade [ADDRESS_970244] immediatel y notify 
the sponsor. Grade 4 reactions will be c ollected as an AE /SAE on the CRF. The event will be 
graded using the AE intensity
 grading scale ( Section 10.2.3).
Further, if a s ystemic event persists bey
ond the end of the e -diary  period, the participant will 
be requested to report that information and/or an y new AEs that develop to the investigator .
The investigator will enter this additional information in the participant’s source n otes and 
CRF.
Table 2. Grading Scale for Systemic Events
Mild
Grade 1Moderate
Grade 2Severe
Grade 3 Grade 4a
Fatigue
(= tiredness)Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospi[INVESTIGATOR_712887]-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 43Table 2. Grading Scale for Systemic Events
Mild
Grade 1Moderate
Grade 2Severe
Grade 3 Grade 4a
Vom iting 1 to 2 times in 
24hours>2 times in 24 hours Requires intravenous 
hydrationEmergency room visit
or hospi[INVESTIGATOR_712888] 2 to 3 loose stools in 
24 hours4 to 5 loose stools in 
24 hours6 or more loose stools
in 24 hoursEmergency room visit
or hospi[INVESTIGATOR_712889]
a.Only an investigator or qualified designee is able to classify a participant’s systemic event as Grade 4, 
after clinical evaluation of the participant or documentation from another medically qualified source 
(eg, emergency room or hospi[INVESTIGATOR_8735]) or contact [CONTACT_6635]. Grade 4 systemic reactions will 
be collected on the AE case report form and assessed by [CONTACT_712922] 10.2.3 .
[IP_ADDRESS]. Fever Monitoring
A digital thermometer will be given to the participant with instructions on how to measure 
oral temperature at home. Temperature will be collected in the evening for 7 day s following 
vaccination (Day  1 through Day 7, where Day  1 is the day  of vaccination) and at any  time 
during the 7 day s following vaccination that fever is suspected.
Fever is defined as an oral temperat ure of ≥38.0°C ( ≥100.4°F) . The highest temperature for 
each day  will be recorded in the e -diary , where possible. Temperatures recorded in degrees 
Fahrenheit will be programmatically  converted to degrees Celsius and then categorized 
according to the scale shown in Table 3during a nalysis.
In the event of a fever on the last day  the diary  was completed, temperature will be measured 
daily  until fever has resolved (1 day  of temperature <38.0°C [<100.4°F]) in order to collect a 
stop date in the CRF.
If a fever of ≥39.0°C (≥102.1°F) is reported in the reactogenicity  e-diary , a telephone contact 
[CONTACT_214345] a site visit is clinically  
indicated. Onl y an investigator or medicall y qualified person is able to confirm a 
participant’s fever as >40.0°C (>104.0°F). If a participant experiences a confirmed fever 
>40.0°C (>104.0°F), the investigator must immediately  notify  the sponsor .Grade 4 fevers 
will be collected on the AE CRF and assessed b y the investigator using the AE intensity 
grading sca le as detailed in Section 10.2.3.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 44Table 3. Ranges for Fever
Mild
Grade 1Moderate
Grade 2Severe
Grade 3 Grade 4a
Fever ≥38.0 °C to 38.4 °C
(100.4 -101.1°F)>38.4 °C to 38.9 °C
(101.2 -102.0°F)>38.9 °C to 40.0 °C
(102.1 -104.0°F)>40.0 °C
(>104.0°F)
a.Only an investigator or qualified designee is able to classify a participant’s fever as Grade 4, after clinical 
evaluation of the participant, docum entation from another medically qualified source (eg, emergency 
room  or hospi[INVESTIGATOR_8735]), or contact [CONTACT_6635]. Grade [ADDRESS_970245] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA , 
immediately  before the administration of the vaccine dose. A negative pregnancy  test result 
will be required prior to the participant’s recei ving the study  intervention. Pregnancy  tests 
may also be repeated if requested by  [CONTACT_1202]/ECs or if required b y local regulations. After 
vaccination, i n the case of a positive confirmed pregnancy , the vaccinated participant may  
remain in the study  for safety  and immunogenicity follow -
up.
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 2.
The definitions of device
-related safet y events (ADEs a nd SADEs) can be found in 
Appendix 5.Device deficiencies are covered in Section 10.5.3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized re presentative), or they  may  arise from clinical findings of the i nvestigator or 
other healthcare providers (clinical signs, test results, etc ).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events tha t meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  (Section 7).
During the active collection period as described in Section 8.3.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to o btain specific follow -
up 
information in an expedited fashion.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 458.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from t he time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention), through to a minimum of 
[ADDRESS_970246] be recorded on the CRF and the SAE reported using 
the Vaccine SAE Reporting Form.
Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has concluded study participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the stud y, and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using the Vaccine SAE Report ingForm.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to [COMPANY_007] Safety  on the Vaccine SAE Report ingForm immediatel y 
upon awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 2. The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_970247] to the CRF 
requirements as described in Section 5.4.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 468.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2.
Care will be taken not to introduce bias when d etecting AEs and/or SAEs. Open- ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety .
Further information on follow -up procedures is given in Appendix 2.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_712923] e thical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investigator safety  reports must b e prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure o ccurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 47exposure inc lude healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  isreportable to [COMPANY_007] Safet y within 
24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing study 
intervention.
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to study  
intervention due to environmental exposure. Below are examples of envi ronmental EDP:
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_17838], ingestion, inhalation, or 
skin contact.
A male 
participant , family member , or healthcare provider wh o has been exposed to 
the study  intervention by  [CONTACT_17838], ingestion, inhalation, or skin contact [CONTACT_712924].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigat or’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occurs in a participant, the investigator must report this information to [COMPANY_007] 
Safety  on the Vaccine SAE Report ingForm and an EDP Supplemental Form, regardless 
of whether an SAE has occurred. Details of the pregnancy will be collected after the start 
of study  intervention and until 6 months af ter study intervention administration.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the Vaccine SAE Report ingForm and EDP 
Supplemental Form. Since the exposure information does not pertain to the participant 
enrolled in the study, the information is not recorded on a CRF; however, a copy  of the 
completed Vaccine SAE Report ingForm is maintained in the investigator site file.
Follow -up is conducted to obtain general information on th e pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 48completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the term inated fetus should be assessed by  [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
thecriteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion.
Neonatal deaths that occur within [ADDRESS_970248] to 
causality , as SAEs. In addition, infant deaths after 1 month should be reported as SAEs 
when the investigator assesses the infant death as related or possibly  related to exposure 
to the study  intervention.
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcome s will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
Exposure during breastfeeding occurs when:
A vaccinated female participant breastfeeds or don ates breast milk to an infant or child at 
any time during her participation in the study .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental exposure 
during breastfeeding is a female family  member or healthcare provider who reports that 
she is breastfeeding after having been exposed to the study  intervention by[CONTACT_17838], 
ingestion, inhalation, or skin co ntact.
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the Vaccine SAE Report ingForm. When exposure 
during breastfeeding occurs in the setting of environmental exposure, the exposure 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 49information does not pertain to the participant enrolled in the study , so the information is not 
recorded on a CRF. However, a cop y of the completed Vaccine SAE Report
ingForm is 
maintained in the investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if t he infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24hours of the investigator’s awareness using the Vaccine SAE Report ingForm, regardless 
of whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed Vaccine SAE Reporting Form must be maintained in 
the investigator site file.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Notapplicable.
8.3.8. Adverse Events of Special Interest
Not applicable.
8.3.9. Medical Device Deficiencies
Medical devices being provided for use in this study  are for the purpose of administering the 
study  intervention . In order to fulfill regulatory  reporting obligations worldwide, the 
investigator is responsible for the detection and documentation of events meeting the 
definitions of device deficiency  that occur during the study  with such devices.
The definition of a medical device deficiency  can be found in Section 10.5.
Note: AEs and/or SAEs that are associated with a medical device deficiency wil l follow the 
same processes as other AEs or SAEs, as outlined in Section 8.3.1 through 8.3.4 and 
Appendix 2 of the protocol .
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be detected, documented, and 
reported during all periods of the study
 in which the medical device is used.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970249] or improper use of the device and even i ntentional misuse, etc.
If the investigator learns of an y device deficiency at an y time after a participant has been 
discharged from the study, and such deficiency  is considered reasonably  related to a medical 
device provided for the study , the investigato r will promptly  notify  the sponsor.
The method of documenting medical device deficiencies is provided in Appendix 5.
[IP_ADDRESS]. Follow -
Up of Medical Device Deficiencies
Follow -up applies to all participants, including those who discontinue study  intervention.
The investigator is responsible for ensuring that follow- up includes an y supplemental 
investigations as indicated to elucidate the nature and/or causality  of the deficiency .
New or updated information will be recorded on a follow -up form with all changes signed 
and dated b y the investigator.
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to the Sponsor
When a device deficiency  occurs: 
1.The investigator notifies the sponsor by  [CONTACT_712925] [ADDRESS_970250] be recorded on the Medical Device Complaint form.
3.If an AE (either serious or nonserious) associated with the device deficiency occurs, 
then the AE m ust be entered into the AE section of the CRF.
4.If an SAE associated with the device deficiency  is brought to the attention of the 
investigator, the investigator must immediately  notify  [COMPANY_007] Safet y of the SAE (see 
Section [IP_ADDRESS]). All relevant details related to the role of the device in the event must 
be included in the Vaccine SAE Report ingform as outlined in Sections [IP_ADDRESS] and 
[IP_ADDRESS].
The sponsor will be the contact [CONTACT_227989].
[IP_ADDRESS]. Regulatory Reporting Requirements for Device Deficiencies
The investigator will promptly  report all device deficiencies occurring with any  medical 
device provided for use in the study  in order for the sponsor to fulfill the legal responsibility  
to notify  appropriate regulatory  authorities and other entities about certain safet y information 
relating to medical devices being used in clinical studies.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 51The investigator, or responsible person according to local requirements (eg, the he ad of the 
medical institution), will comply  with the applicable local regulatory  requirements relating to 
the reporting of device deficiencies to the IRB/EC.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by[CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under study  may  occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE 
Report ingForm to [COMPANY_007] Safety 
Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention.
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study  participant.
The administration of expi[INVESTIGATOR_214312].
The administration of an inco rrect study  intervention.
The administration of an incorrect dosage.
The administration by  [CONTACT_404249].
The administration of study  intervention that has undergone temperature excursion from 
the specified storage range, unless it is determined by  [CONTACT_214348].
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a me dication dosing error, the sponsor should be notified within 24 hours.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 52Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within 24 hours on a Vaccine SAE 
Report ingForm only when associated with an SAE .
8.4.Pharmacokinetics
Pharmacokinet ic parameters are not evaluated in this study .
8.5.Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.6.Biomarkers
Biomarkers are not evaluated in this study .
8.7.Immunogenicity Assessments
Immunogenicit y assessments are described in Section 8.1.2.
8.8.Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study .
8.9.Study Procedures
8.9.1.
Visit 1 –Vaccination (Clinic, Day 1)
Before enrollment and before an y stud y-related procedures are performed, voluntary , written 
study -specific informed consent will be obtained from the participant. Each signature [CONTACT_712932] y dated b y the signatory.
The investigator or his or her designee will also sign and date the ICD. A copy  of the signed 
and dated ICD must be given to the participant. The source data must reflect that the 
informed consent was obtained before participation in the study .
It is anticipated that the procedures below will be conducted in a stepwise manner; ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.
Obtain written informed consent from th e participant before performing any  
study -specific procedures.
Assign a single participant identifier using the IRT system.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 53Obtain and record the participant demograph y (including complete date of birth 
[dd-Mmm -YYYY], sex, race, racial designation, and e thnicity ). The full date of birth will 
be collected to criticall y evaluate the immune response and safet y profile by [CONTACT_654].
Obtain and record an y medical history  of clinical significance.
Perform a clinical assessment. If the clinical assessment indicates th at a phy sical 
exam ination is necessary to comprehensivel y evaluate the participant, perform a ph ysical 
examination and evaluate vital signs and record any findings in the source documents 
and, if clinically significant, record on the medical history CRF.
Measure and record prevaccination temperature.
Prior to vaccination, perform a urine pregnancy  test on WOCBP as described in
Section 8.2.5. Record the result in the source documents. A negative pregnancy  test result 
will be required prior to the participant’s receiving the study  intervention .
Discuss contraceptive use as descr
ibed in Section 10.3.4.
Obtain details of an y nonstudy  vaccinations as described in 
Section 6.8.
Review concomitant medication use as described in Section 6.8.
Ensure and document that all the inclusion criteria and none of the exclusion criteria are 
met.
Ensure that the participant meets none of the temporary  delay  criteria as described in 
Section 5.5. If delay criteria are met, reschedule the Visit 1blood draw and 
randomization/vaccination for a later date.
Prior to vaccination, collect a blood sample of approximately  20mL for antibody  
assessment.
Obtain the participant’s randomization number and study  intervention kit number using 
the IRT s ystem. Refer to the I RT manual for further instructions on this proc ess.
Issue a measuring device to measure local reactions at the injection site and a 
thermom eter for recording dail ytemperatures.
Explain the e -diary  technologies available for this study  (Section 8.2.3) , and assist the 
participant in downloading the e
-diary  application onto the participant’s own device or, if 
required ,issue a sponsor -provisioned e-diary .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 54Work with the participant to set up thedevice/e -diary  and provide training on daily  
e
-diary  completion . Ask the participant to complete the reactogenicit y e-diary  each 
evening between 6 pm and midnight, starting on Day 1 and completing on Day 7, w here
Day 1 is theday of vaccination.
Qualified site staff member(s) will administer a single dose of study  intervention into the 
deltoid muscle of the nondominant arm (preferred a rm).
Observe the participant for an y acute reactions for at least [ADDRESS_970251] an y acute reactions including the time of onset, in the 
participant’s source documents, on the AE page of the CRF, and on the Vaccine SAE 
Report ingForm ifapplicable.
Provide 
the participant with an ECC and instruct the participant on its use.
Ask the participant to contact [CONTACT_214350] y if he/she 
experiences an y of the following reactions from Day  1 to Day  7 after vaccination (where 
Day 1 is the day  of vaccination) to determine if an uns cheduled reactogenicity  visit is 
required (Section 8.9.3):
Fever ≥39.0°C (≥102.1°F ).
Redness or swelling at the inject
ion site measuring >20 measuring device units 
(greater than 10 cm).
Severe pain at the injection site.
Any severe s ystemic event.
OR
Any emergency  room attendance or hospi[INVESTIGATOR_059] .
Advise the participant that study  staff may  contact [CONTACT_712926] e -diary .
Advise the participant to inform the study  staff of any  AEs and SAEs that occur for the 
duration of the study as described in Section 8.3.
Request that 
the participant bring the completed e -diary  to the next visit .
Complete the source documents.
The investigator or an authorized designee completes the CRFs and the blind ed 
dispenser/administrator completes the study  intervention accountability  records.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 55The investigator or appropriately  qualified designee reviews the daily e-diary  data online 
following vaccination to evaluate participant compliance and as part of the ongoi ng 
safet y review.
8.9.2. Visit 2 – 1- Month Follow -Up (Clinic, 28 to 35 Days After Visit 1)
Record details of an y nonstudy  vaccinations andconcomitant medications as described in 
Section 6.8.
Collect a blood sample of approximately  80mL for antibody  assessment.
Review the participant’s e -diary  data. Collect stop dates of an y e
-diary  events ongoing on 
the last day  that the e -diary was completed and record stop dates in the CRF. Collect any  
sponsor -provisioned e-diary .
Record AEs and SAEs as described in Section 8.3. Obtain and record an y missing AE 
stop dates.
Complete the source documents.
The investigator or an authorized designee completes the CRF.
8.9.3. Unscheduled Reactogenicity Visits for a Grade 3 or Suspected Grade 4 Reaction
If a severe local reaction ( Section [IP_ADDRESS]), severe systemic event ( Section [IP_ADDRESS] ), or fever
≥39.0°C ( ≥102.1 °F) (Section [IP_ADDRESS] ) is reported in the e- diary , a telephone contact [CONTACT_712921] a site visit is clinically  indicated. If a 
suspected Grade [ADDRESS_970252] or site visit should occur to confirm whether the event meets the 
criteria for Grade 4.
A site visit or referral to a healthcare facility  should be scheduled as soon a s possible to 
assess the extent of the reaction, unless:
The participant is unable to attend the unscheduled visit, or
The reaction is no longer present at the time of the contact, or
The participant recorded an incorrect value in the e- diary  (confirmation of an e -diary  data 
entry  error), or
The investigator or appropriate designee determines that an unscheduled visit 
(Section 8.9.3) is not required.
This contact [CONTACT_214356]’s source notes and in the CRF.
Any ongoing reactions must be assessed at the next scheduled visit.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 56The reactogenicity events should be assessed by [CONTACT_1720] a medically qualified 
member of the site staff such as a study physician or a study nurse, as applicable to the investigator’s local practice or healthcare facility, who will:
•Measure body temp erature and record any fever ( Table 3 ).
•If present, measure the minimum and maximum diameters of redness at the injection site.
•If present, measure the minimum and maximum diameters of swelling at the injection 
site.
•Assess any injection site pain in accordance with the reactogenicity grading scale 
provided in Table 1 .
•Assess any systemic events (fatigue, headache, vomiting, nausea, diarrhea, muscle pain, 
or joint pain) that are present in accordance with the reactogenicity grading scale 
provided in Table 2 .
•Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
•Record AEs and SAEs as described in Section [IP_ADDRESS].
•Complete the participant’s source documents.
•The investigator or an authorized designee will complete the 
unscheduled-visit-assessment CRF.
9. STATISTICAL CONSIDERATIONS
Methodology for summary and statistical analyses of the data collected in this study is 
described here and further detailed in the SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
9.1.1. EstimandsThe estimands corresponding to each primary  objective are described in 
Section 3 .
The estimands to evaluate the immunogenicity objectives are based on the evaluable 
immunogenicity population ( Section 9.2 ). These estimands estimate the vaccine effect in the 
hypothetical settings where participants follow the study schedules and protocol requirements as directed. Missing serology results will not be imputed, as MCAR is assumed.CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 57In the primary  safet y objective evaluations, completely  missing reactogenicity  e -diary  data 
will not be imputed. Missing AE dates will be imputed according to [COMPANY_007] safet y rules. No 
other missing information will be imputed in t he safet y analysis.
9.1.2. Statistical Hypotheses
This study  has 1 primary  immunogenicit y objective, which is to demonstrate that the immune 
responses for RSV A and RSV B induced b y 3 lots of RSVpreF are equivalent. The objective 
will be evaluated at 1 month afte r vaccination for RSV A and RSV B using the evaluable 
immunogenicit y population.
The null hy pothesis (H 0) for lot consistency  for RSV A and RSV B is as follows:
H0: |ln(μ 1) -ln(μ 2)| ≥ln(1.5) or |ln(μ 1) -ln(μ 3)|≥ln(1.5) or |ln(μ 2) -ln(μ 3)|≥ln(1.5)
where ln( 1.5) corresponds to a 
1.5-fold equivalence margin, and ln(μ1), ln(μ2), and ln(μ3)
are the natural log of the geometric mean of RSV antigen -specific NT s from participants 
receiving RSVpreF in Group 1, Group 2, and Group 3, respectivel y, measured 1 month after 
vaccination.
Lot consistency will be declared if the 2 -sided 95% CI  for the ratio of GMTs for every  pair of 
RSVpreF lots is contained in the interval (0. 667, 1.5 ), for both antigens simultaneously .
9.1.3. Multiplicity Adjustment
No multiplicity  adjustment will be applied for this study . The primary  objective of 
equivalence will be achieved only  if the 
1.5-fold equivalence criterion is met for every pair of 
between -lot comparisons from 3 lots and for both RSV A and RSV B antigens 
simultaneously . Each of the 6 statistical tests (3 pairwise comparisons between lots × 2 RSV 
antigens) will usea 2-sided alpha level of 0.05.
9.2.Analysis Sets
Population Description
Enrolled All participants who sign the ICD.
Randomly assigned to study 
interventionAll participants who are assigned a randomization number in the IRT system.
Evaluable immunogenicity Allparticipants who are eligible, receive the study intervention to which they 
were randomized, have valid and determinate immunogenicity result from the 
blood sample collected within an appropriate w indow  at [ADDRESS_970253] 1 
valid and determinate assay result after vaccination.
Safety All randomized participants who receive study intervention .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 589.3. Statistical Analyses
The SAP will be developed and finalized before any  anal yses are performed and will 
describe the anal yses and procedures for accounting for missing , unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. General Considerations
Unless stated otherwise, “vaccine group” in this section refers to participants receiving an y 1 
of the 3 RSVpreF lots or placebo. CIs for all endpoints in the statistical analy siswill be 
presented as 2-sided at the 95% level unless specified otherwise.
For all the immunogenicity  endpoints, the analy sis will be based on the evaluable 
immunogenicit y populat ion. An additional anal ysis will be performed based on the mI TT 
population if there is a large enough difference in sample size between the mI TT population 
and the evaluable immunogenicity  population. Participants will be summarized according to 
the vaccin e group to which they  were randomized.
The safet y analyses will be based on the safet y population. Participants will be summarized
by [CONTACT_712927] y received.
[IP_ADDRESS]. Analyses for Binary Data
Descriptive statistics for categorical variables (eg, proportions) are the percentage (%), the 
numerator (n) and the denominator (N) used in the percentage calculation, and the 95% CIs 
where applicable.
The exact 95% CI for binary  endpoints for each group will be computed using the 
Fdistribution (Clopper -Pearson).
[IP_ADDRESS]. Analyses for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
SD, minimum, and maximum.
[IP_ADDRESS].1. Geometric Mean Ratios
The GMRs will be calculated as the mean of the difference of logarithmically  transformed 
assay  results between 2 vaccine groups and exponentiating the mean. Two -sided CI s will be 
obtained by  [CONTACT_214359] s using Student’s t -distribution for the mean difference of the 
logarithmicall y transformed assay results and exponentiating the confidence limits.
[IP_ADDRESS].2.
Geometric Means
The geometric means will be calculated as the mean of the assay  results after making the 
logarithm transformation and then exponentiating the mean to express results on the original 
scale. Two-sided 95% CIs will be obtained by  [CONTACT_214360], 

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 59calculating the 95% CI with reference to Student’s t-distribution, and then exponentiating the 
confidence limits.
9.3.2. Primary Endpoint(s)
Endpoint Statistical Analysis Methods
Immunogenicity GMRs of RSV NTs for each between-lot comparison (Group 1/Group 2, 
Group 1/Group 3, and Group 2/Group 3) for RSV A and RSV B at 1 month after vaccination will be provided along with associated 2-sided 95% CIs ( Section [IP_ADDRESS].1 ).
Using a 1.5-fold equivalence margin, lot consistency will be declared if 
the 2-sided 95% CI for each GMR is contained in the interval (0.667, 1.5).CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 60Endpoint Statistical Analysis Methods
Safety Descriptive statistics will be provided for each reactogenicity  endpoint 
in the pooled RSVpreF lots ( Groups 1, 2, and 3) and placebo. Local 
reactions (redness, swelling
,and pain at the injection site) and s ystemic 
events (fever, fatigue, headache, vomiting, nausea, diarrhea, muscle 
pain, and joint pain) from Day  1 through Day  7 after vaccination will be 
presented b y severit y and cumulatively across severity levels. 
Descriptive summary  statistics will include counts and percentages of 
participants with the indicated endpoint and the ass ociated 
Clopper -Pearson 95% CIs ( Section [IP_ADDRESS]).
AEs and SAEs will be categorized according to MedDRA terms. 
Counts, percentages, and the associated Clopper -
Pearson 95% CIs of 
AEs and SAEs after vaccination will be provided for the pool ed 
RSVpreF lots and placebo.
A 3-tier approach will be used to summarize AEs. For both Tier 1 and 
Tier 2 events, the 95% CIs for the difference in percentage of 
participants reporting the events between the pooled RSVpreF lots and 
placebo will be calculate d using the test statistic proposed b y Miettinen 
and Nurminen;22in addition, for Tier [ADDRESS_970254] 1% 
inthe pooled RSVpreF group or in the placebo group. 
9.3.3. Secondary Endpoint(s)
Not a pplicable.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, [ADDRESS_970255] to the 2 RSV antigens.
Pairwise lot-consistency comparisons will be based on the GMRs and the corresponding 95% 
CIs. For both antigens, it is assumed that true differences between lots are not larger than 0(on the natural log scale). The SDs of the log titers for RSV A and RSV B are based on Study C3671001 data.
With 225 evaluable participants per vaccine group and the above assumptions, the power is 
93.3% for declaring the overall equivalence of the 3 RSVpreF lots for both RSV A and RSV B.CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 62Allowing for a nonevaluable rateof approximately  10% , up to 1000 participants willbe 
enrolled in the study  to provide the required sample size of approximately  
900participants 
for the evaluable population analy sis. Participants who withdraw or are withdrawn from the 
study  after randomization will not be replaced, regardless of the rea son for withdrawal.
Table 4. Power for the Primary Immunogenicity Objective (Lot Consistency)
Endpoint Within -
Lot 
SD (Log 
Scale)aMaximum Lot 
Difference
(Log Scale)Consistency 
MarginNumber of Evaluable 
Participants per 
Vaccine GroupPower to 
Declare 
Consistencyb
RSV A 0.96 0 1.5-fold 225 98.5%
RSV B 1.07 0 1.5-fold 225 94.7%
Overall pow er to declare consistency for RSV A and RSV B simultaneously 93.3%
a.The reference study is C3671001.
b.The pow er to declare equivalence betw een all 3 pairwise comparisons assuming a mean difference of 0 
betw een any 2 RSVpreF lots, at a 0.05 alpha level (2 -sided).

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 6310.SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applic able ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg, advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to elimina te an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The inves tigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical stud ies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970256], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the study  and for 
1year after com pletion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all questions regarding the study .The 
participant should be giv en sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that me ets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study , the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data.
The participant must be informed that his/her pers onal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in t he study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970257] current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
Participants who are rescreened may  be required to sign a new ICD as per IRB, local 
regulations, etc.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regardin g the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password -protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential person al data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the proc essing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC .
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOP s.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 66www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study is conducted. These results a re 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_712928].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corre sponding study  results are 
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, un der Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient
-level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individua ls 
requesting access for commercial/competitive or legal purposes.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 6710.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator m ust ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters 
that are monitor ed during the stud y. Important deviations 
from the QTLs and any remedial actions taken will be summarized in the clinical study  
report .
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and prov ide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained b y the investigator for [ADDRESS_970258] ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 68The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  retain 
notification in relation to the study . Furthermore, the investigator will cooperate with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow the 
sponsor or its agent, whenever feasible, to be present during the inspection. The investigator 
site and inves tigator will promptly  resolve an y discrepancies that are identified between the 
study  data and the participant's medical records. The investigator will promptly  provide 
copi[INVESTIGATOR_19946]. Before response submissi on to 
the regulatory  authorities, the investigator will provide the sponsor or its agents with an 
opportunity  to review and comment on responses to any  such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant a nd substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the monitoring plan , 
which is maintained by  [CONTACT_456] .
Description of the use of the computerized sy stem is documented in the data management 
plan, which is maintained by  [CONTACT_456].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the r ight to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have be en collected and a study -site closure visit has been performed.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 69The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the I RB/EC 
or local health authorities, the sponsor's procedures, or the I CH GCP guidelines.
Inadequate recruitment of participants by  [CONTACT_093].
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant
and should assure 
appropriate participant therap y and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights .
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first.
The i nvestigator agrees to refer to the primary  publication in any  subsequent publications, 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  informat ion and to 
provide comments, and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y or [COMPANY_007] intervention -related 
information necessary  for the appropriate scientific prese ntation or understanding of the 
study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites. I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multice nter studies only  in their entirety and not as 
individual site data. I n this case, a coordinating investigator [INVESTIGATOR_78246].

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 70Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements.
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_20015]/study  portal or other electronic s ystem.
To facilitate access to appropriate ly qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] Call Center number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investi gator, site staff, and stud y team. The ECC is to be used by [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The [COMPANY_007] Call Center number should o nly be 
used when the investigator and site staff cannot be reached. The [COMPANY_007] Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 7110.2. Appendix 2: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -
Up, and Reporting
10.2.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally  associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator .Any abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ingsymptoms .
Requires additional diagnostic testing or medical/surgical intervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even 
though it may have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AEor SAE unless it is an intentional overdose taken with possible 
suicidal/self
-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 72Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.2.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one or 
more of the criteria listed below :
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 73d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) ,thatmay interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or non- pathogenic , is considered serious.
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_712929], such as significant medical 
events that may  jeopardize the participant or may  require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition.
These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 7410.2.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAE son the Vaccine SAE Report ingForm to [COMPANY_007] Safety throughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; 
(2)nonserious AEs ; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure.
It should be noted that the Vaccine SAE Report ingForm for reporting of SAE information 
is not the same as the AE page of the CRF. When the same data are collected, the forms 
must b e completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE
Report ingForm for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine SAE
Report ingForm to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding .All AEs or SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding .
Note: Instances of EDP 
or EDB not associated 
with an AE or SAE are 
not captured in the CRF.All instances of EDP are 
reported (whether or not there 
is an associated SAE) .*
All instances of EDB are 
reported (whether or not there 
is an associated SAE).**
Environmental or 
occupational exposure to 
the product under stud y to 
a non -participant (not 
involving EDP or EDB).None. Exposure to a 
study  non- participant is 
not collected on the CRF.The exposure (whether or not 
there is an associated AE or 
SAE) must be reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to [COMPANY_007] 
Safety using the Vaccine SAE Report ingForm  and EDP Supplemental Form; if the EDP is
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the Vaccine SAE Report ing
Form .
** EDB is reported to [COMPANY_007] Safety using the Vaccine SAE Report ingForm ,which would also include 
details of any SAE that might be associated w ith th e EDB.
***Environmental or occupational exposure: AEsor SAEs associated with occupational exposure are 
reported to [COMPANY_007] Safety using the Vaccine SAE Report ingForm .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 75When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic reports) 
related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to [COMPANY_007] Safety  in lieu of completion of the Vaccine SAE Report ingForm /AE
or SAE CRF page.
There may  be instances when copi[INVESTIGATOR_404205] y .In this case, all partici pant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_404204] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the following categories:
GRADE If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, SEVERE, or LIFE- THREATENING to 
describe the maximum intensity  of the AE. For purposes of consistenc y, 
these intensity  grades are defined as follows:
1 MILD Does not interfere with participant's usual 
function.
2 MODERATE Interferes to some extent with participant's usual 
function.
3 SEVERE Interferes significantl y with participant's usual 
function.
4 LIFE -THREATENING Life-threatening consequences; urgent 
intervention indicated.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 76Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention and 
each occurrence of each AE or SAE. The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also cons ult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE or SAE and has provided an assessment of causality .
There may  be si tuations in which an SAE has occurred, and the investigator has minimal 
information to include in the initial report to the sponsor . However, it is very important 
that the investigator always make an assessment of causality for every event before 
the initi al transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the event, 
then the event will be handled as “related to study intervention” for reporting purposes, 
as defined by [CONTACT_456] . In addition, if the investigator determines that an SAE is 
associated with study  procedures, the investigator must record this causal relationship in 
the source documents and CRF, and report such an assessment in the dedicated section 
of the Vaccine SAE Report ingForm and in accordance with the SAE reporting 
requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_456],
to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide [COMPANY_007] Safety  with a cop y of an y postmortem 
findings ,including histopathology .
New or updated information will be recorded in the originally  submitted documents .
The investigator will submit any  updated SAE data to the sponsor within 24 hours of 
receipt of the information.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 7710.2.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic data 
collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next s ection) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data become 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to preve nt the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, then the site c an report this information on a paper SAE form (see next section) 
or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via Vaccine SAE Report ingForm
Facsimile transmission of the Vaccine SAE Report ingForm is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the fac simile is not working , notification by  [CONTACT_20021] a cop y of the Vaccine SAE Report ingForm sent b y overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Report ingForm pages within the designated 
reporting time frames.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 7810.3. Appendix 3: Contraceptive and Barrier Guidance
10.3.1. Male Participant 
Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least [ADDRESS_970259] dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent from said heterosexual intercourse.
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom when having sexual intercourse with a woman of 
childbearing potential who is not currently  pregnant.
Inaddition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.3.4).
10.3.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.3.3).
OR
Is a WOCBP and using an acceptable contraceptive method as described below 
during the intervention period (for a minimum of [ADDRESS_970260] dose of 
study  intervention). The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 7910.3.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, ameno rrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examinatio n, or medical history  
interview. The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT.
A female on HRT and whose menopausal status is in doubt will be required to us e 
one of the nonestrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y. Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
10.3.4. Contraception Methods
Contraceptive use b y men or WOCBP should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 801.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner:
A vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly  effective method of 
contraception should be used. The spermatogenesis cy cle is approximately  90 day s.
6.Combined (estrogen- andprogestogen-containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal .
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be evaluated 
in relation to the dura tion of the study  and the preferred and usual lifest yle of the 
participant.
9.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom with or without spermicide.
11.Cervical cap, diaphr agm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 8110.4. Appendix 4: Liver Safety: Suggested Actions and Follow -Up Assessments
Potential Cases of Drug- Induced Live r Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase eleva tions are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participants who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptors” or are “susceptible.”
LFTs are not required as a routine safety  monitoring procedure in this study . However, 
should an investigator deem it necessary  to assess LFTs because a participant presents with 
clinical signs/s ymptoms, such LFT results should be managed and followed as described 
below.
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several days or weeks. The increase in TB ili typi[INVESTIGATOR_216474]/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same laboratory  sample). In rare instances, by [CONTACT_22858], 
AST/AL T values might have decreased. Thi s occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be con sidered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying condition s. Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline va lues within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORTBili v alues above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 82Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_970261] and AL T and TBili for suspected Hy’s law 
cases, additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consid eration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A d etailed history , including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consump tion, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for a cute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen /paracetamol drug and/or protein adduct levels may  be warranted.
All cases demonstrated on repeat testing as meeting the laborat ory criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities .
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have exclu ded an alternative etiology .

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 8310.5. Appendix 5: AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs, and Device Deficiencies:
Definition sand Procedures for Recording, Evaluating, Follow -Up, and Reporting in 
Medical Device Studies
Definitions of a Medical Device Deficiency
The definitions and procedures detailed in this appendix are in accordance with I SO [ADDRESS_970262] 2017/745 for clinical device research (if applicable) .
Both the investigator and the sponsor will comply  with all local reporting requirements for 
medical devices.
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.[ADDRESS_970263] of sponsor 
medical devices).
10.5.1. Definition of AE and ADE
AE and ADE Definition
An AE is defined in Appendix 2 ( Section 10.2.1).
An ADE is defined as an AErelated to the use of an investigational medical device. 
This definition includes any  AEs resulting from insufficient or inadequate 
instructions for use, deploy ment, implantation, installation, or operation, or any  
malfunction of the investigational medical device as well as an y event resulting 
from use error or from intentional misuse of the investigational medical device.
10.5.2. Definition of SAE, SADE ,and [LOCATION_003]DE
SAE Definition
An SAE is defined in Appendix 2 ( Section 10.2.2).
SADE Definition
An SADE is defined as an adverse device effect that has resulted in an y of the 
consequences characteristic of an SAE .
Any device deficiency  that might have led to an SAE if appropriate action had not 
been taken, intervention had not occurred, or circumstances had been less fortunate.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 84[LOCATION_003]DE Definition
A [LOCATION_003]DE is a serious adverse device effect thatby [CONTACT_5942], incidence, severity , or 
outcome has not been identified in the current version of the risk anal ysis 
management file .
10.5.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its identity , 
quality , durabilit y, reliability , safet y, or performance. Device deficiencies include 
malfunctions, use errors, and inadequate information supplied by  [CONTACT_3455] .
10.5.4. Recording/Reporting and Follow -Upof Medical Device Deficiencies
Device Deficiency Recording
When a device deficiency  occurs, it is the responsibility  of the i nvestigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant device deficiency  information in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice and will also capture the required information on the Medical Device 
Complaint form.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of following the reporting process described 
in the Medical Device Complaint form.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] 
Safety . In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copi[INVESTIGATOR_296044] y.
If the investigator determines that the medical device deficiency  may  have injured 
the participant (ie, the medical device deficiency is associated with an AE or SAE), 
then the investigator will attempt to establish a diagnosis of the event based on 
signs, s ymptoms, and/or other clinical information. Whenever possible, the 
diagnosis will be documented in the participant’s medical record and recorded as the 
AEor SAE rather than the individual signs/sy mptoms. Requirements for recording 
and reporting an AE or SAE are provided i n Appendix 2(Section 10.2.3).

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 85For device deficiencies, it is very  important that the investigator describes any  
corrective or remedia l actions taken to prevent recurrence of the incident .
A remedial action is an y action other than routine maintenance or servicing of a 
medical device where such action is necessary  to prevent recurrence of a device 
deficiency . This includes any  amendment to the device design to prevent 
recurrence.
Assessment of Causality Occur ring in Conjuncti on With a Medical Device Deficiency
If an AE or SAE has occurred in conjunction with a medical device deficiency , the 
investigator must assess the relationship between each occurrence of the AE or SAE 
and the medical device deficiency . The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administr ation will be considered and investigated.
The investigator will also consult the IB in his/her assessment.
For each device deficiency , the investigator must document in the medical notes 
that he/she has reviewed the device deficiency  and has provided an assessment of 
causality .
There may  be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is 
very important that the investigator alway s make an assessment of causality for 
every  event before the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_712890] f ollow -
up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 86Follow -Up of Medical Device Deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the device deficiency  as fully  as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
New or updated information regarding the nature of the device deficiency  will be 
recorded in the originall y completed Medica l Device Complaint form.
New or updated information regarding an y SAE that was potentially associated with 
the medical device deficiency  will be submitted to [COMPANY_007] Safety  on the Vaccine SAE
Report ingForm within [ADDRESS_970264] be performed according to the processes 
described in Appendix 2 ( Section 10.2.4).
10.5.6. Reporting of SADEs
SADE Reporting to [COMPANY_007] Safety
Note: There are additional reporting obligations for medical device deficiencies that are 
potentially  related to SAEs (ie ,a SADE) that must fulfill the legal responsibility  to notify  
appropriate regulatory  authorities and other entities about certain safet y information relating 
to medical devices being used in clinical studies.
Any device deficiency  that is associated with a n SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency .
The sponsor shall review all device deficiencies and determine and document in 
writing whether they  could ha ve led to an SAE. These shall be reported to the 
regulatory  authorities and I RBs/ECs as required by  [CONTACT_2091].

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 8710.6. Appendix 6: Alternative Measures During Public Emergencies
Thealternative study  measures described in this section areto befollowed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for theduration of 
the COVID -19 pandemic globall y and will become effective for other public emergencies 
only upon written notification from [COMPANY_007].
Use of these alternative study  measures 
isexpected to cease upon the return of business as 
usual (including the lifting of an y quarantines and travel bans/advisories).
10.6.1. Telehealth Visits
In the event that in-clinic study  visits cannot be conducted, every  effort should be made to 
follow up on the safet y ofstudy participants at scheduled visits per the Schedule of 
Activities or unscheduled visits. Telehealth visits may be used to continue to assess 
participant safety and collect data points. Telehealth includes the exch ange of healthcare 
information and services via telecommunication technologies (eg, audio, video, 
video- conferencing software) remotel y, allowing the participant and the investigator to 
communicate on aspects of clinical care, including medical advice, re minders, education, and 
safet y monitoring. The following assessments must be performed during a telehealth visit:
Review and record an y AEs andSAEs since the last contact. Refer to Section 8.3.
Obtain details of an y nonstudy  vaccinations , concomitant medications ,and treatments 
as described in 
Section 6.8.
Confirm that the participant is adhering to the contraception method(s) required in the 
protocol.
Study  participants must be reminded to promptl ynotify site staff about an y change in their 
health status.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 8810.7. Appendix 7: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
ADE adverse device effect
AE adverse event
Al(OH) [ADDRESS_970265]-in-human
FI-RSV formalin -inactivated respi[INVESTIGATOR_712891] -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMFR geometric mean fold rise
GMT geometric mean titer

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C3671014Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 89Abbreviation Term
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IM intramuscular
IND investigational new drug application
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability Log
IRB institutional review board
IRT interactive response technology
ISO International Organization for Standardization
IV intravenous
IWR interactive Web- based response
LAIV live attenuated influenza vaccine
LFT liver function test
LMIC low- and middle-income country 
LRTI lower respi[INVESTIGATOR_712892]-RSV RSV-associated lower respi[INVESTIGATOR_712893]-to-treat
msLRTI moderate to severe lower respi[INVESTIGATOR_301865]
N/A not applicable
NT neutralizing titer
PCR polymerase chain reaction
PFS prefilled syringe
PPE personal protective equipment
PT prothrombin time
QTL quality tolerance limit
RSV respi[INVESTIGATOR_712894] A respi[INVESTIGATOR_712895] A
RSV B respi[INVESTIGATOR_712895] B
RSVpreF respi[INVESTIGATOR_712896] F subunit vaccine
RT-PCR reverse transcription– polymerase chain reactionCCI
CCI
PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970266]
WOCBP woman/women of childbearing potential

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 14
Final Protocol Amendment 1, 08 Feb 2022
PFIZER CONFIDENTIAL
Page 9111.REFERENCES
1Meissner HC. Respi[INVESTIGATOR_227899]. Chapter 225. In: Long SS, Prober CG, 
Fischer M, eds. Principles and practice of pediatric infectious diseases. 5th ed. 
Philadelphia, PA: Elsevier; 2018:1162-5.
2Hall CB, Weinberg GA, Blumkin AK, et al. Respi[INVESTIGATOR_712897]–associated 
hospi[INVESTIGATOR_404215] 24 months of age. Pediatrics. 
2013;132(2):e341 -
8.
3Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden 
estimates of acute lower respi[INVESTIGATOR_712898] 2015: a systematic review and modelling study . Lancet .
2017;390([ZIP_CODE]):946-58.
4Scheltema NM, Gentile A, L ucion F, et al. Global respi[INVESTIGATOR_227899] -associated 
mortality  in young childre n (RSV GOLD): a retrospective case series. Lancet Glob
Health. 2017;5(10):e984 -91.
5Parikh 
RC, McL aurin KK, Margulis AV, et al. Chronologic age at hospi[INVESTIGATOR_712899]. Infect
Dis Ther .2017;6(4):477 -86.
6American 
Academy  of Pediatrics Committee on Infectious Diseases and Bronchiolitis 
Guidelines Committee. Policy  statement —updated guidance for palivizumab 
prophy laxis among infants and y oung children at increased risk of hospit alization for 
respi[INVESTIGATOR_712900]. Pediatrics
.2014;134(2):415 -20.
7Blanken MO, Rovers MM, Molenaar JM, et al. Respi[INVESTIGATOR_712901] y preterm infants. N Engl J Med.2013;368(19):1791 -
9.
8Stein RT, Sherrill D, Morgan WJ, et al. Respi[INVESTIGATOR_696] s yncytial virus in earl y life and risk 
of wheeze and allergy  by [CONTACT_654] 13 y ears. Lancet .1999;354(9178):541-5.
9Weber MW, Mulholland EK, Greenwood BM. Respi[INVESTIGATOR_227955]. Trop Med Int Health. 1998;3(4):268 - 80.
10Glezen 
WP, Taber LH, Frank AL, et al. Risk of primary  infection and reinfection with 
respi[INVESTIGATOR_227899]. Am J Dis Child .1986;140(6):543-6.
11American Academy  of Pediatrics. Respi[INVESTIGATOR_712902]. In: Kimberlin DW, Brad y 
MT, Jackson MA, et al , eds. Red book: [ADDRESS_970267] ed. I tasca, IL: American Academ y of Pediatrics; 2018:682 -92.

PF-06928316 (Respi[INVESTIGATOR_14250] [RSV] Vaccine)
Protocol C36710 [ADDRESS_970268] effectiven ess of respi[INVESTIGATOR_712903]: a critical and s ystematic review. Pharmacoeconomics.
2010;28(4):279 -93.
13Falsey  AR, Hennessey  PA, Formica MA, et al. Respi[INVESTIGATOR_227963] y and high -risk adults. N Engl J Med. 
2005;352(17):1749 -59.
14Murata Y, Falsey  AR. Respi[INVESTIGATOR_227962]. Antivir Ther.
2007;12(4 Pt B):[ADDRESS_970269] Dis. 2019;69(2):197-203.
16Sundaram 
ME, Meece JK, Sifakis F, et al. Medically  attended respi[INVESTIGATOR_712904] ≥50 y ears: clinical characteristics and outcomes. Clin I nfect 
Dis. 2014;58(3):342
-9.
17Belongia EA, King JP, Kieke BA, et al. Clinical features, severity , and incidence of 
RSV illness during 12 consecutive seasons in a community  cohort of adults ≥[ADDRESS_970270] Dis. 2018;5(12):ofy316.
18Wyffels V, Karibury o F, Gavart S, et al. A real- world anal ysis of patient characteristics 
and predictors of hospi[INVESTIGATOR_712905]. Adv Ther. 2020;37(3):[ADDRESS_970271] Dis Ther. 2021;10(Suppl 1):S47 -S60.
20US Food and Drug Administration, Center for Biologics Evaluation and Research. 
Guidance for i ndustry : toxicity  grading s cale for healthy  adult and a dolescent volunteers 
e
nrolled in preventive vaccine clinical trials.Rockville, MD: Center for Biologics 
Evaluation and Research; Sep 2007.
21US Census Bureau. QuickFacts: [LOCATION_002]. Available from: 
https://www.census.gov/quickfa cts/fact/table/US/PST045219. Accessed: 06 Aug 2021.
22Miettinen O, Nurminen M. Comparative anal ysis of two rates. Stat Med .1985;4 (2):213-
26.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	
	

	


'RFXPHQW 7LWOH !"#$%&'()"%%&*+,"-+,($%,"+&-&$.#&,
,"%!.*%/.&"0,*.". "!"./.&,"#+(,(./$%(''*$&1"$((./&,&.!&#"!(#.&#/!/$/.(,0(#*!2#!03#"*!(&$!*+*$(.($ ",. /%*,.!
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\

--
	66
 
7

--
	6
6
 
7[COMPANY_003]
[COMPANY_003]